EXCERPT : BNB trades at $627 with neutral momentum after 5.46% daily gains. Technical analysis suggests potential test of $667 resistance, though bears target $572 support if momentum fails. BN...
EXCERPT: BNB trades at $627 with neutral momentum after 5.46% daily gains. Technical analysis suggests potential test of $667 resistance, though bears target $572 support if momentum fails.
What Crypto Analysts Are Saying About Binance Coin While specific analyst predictions are limited in recent trading sessions, available forecasts from earlier this month remain relevant. Peter Zhang noted on January 5th that "BNB trades at $883 with neutral RSI and mixed signals. Analysts forecast Binance Coin reaching $950-$1,050 by February 2026 despite current bearish momentum," targeting the $950-$1,050 range.
Felix Pinkston echoed similar sentiment on January 7th, stating "BNB trades at $883 with neutral RSI and bearish MACD momentum. Analysts forecast Binance Coin reaching $950-$1,050 range by February 2026 despite current consolidation phase."
However, these predictions were made when BNB traded significantly higher at $883. Current market conditions suggest a more conservative Binance Coin forecast is warranted given the token's decline to current levels around $627.
BNB Technical Analysis Breakdown BNB's technical picture presents mixed signals with the token trading at $627.47 after a solid 5.46% daily gain. The RSI reading of 41.61 indicates neutral territory, suggesting neither overbought nor oversold conditions.
The MACD histogram sits at exactly 0.0000, signaling a potential momentum shift, though current readings lean bearish with MACD at -39.24. This divergence between recent price action and momentum indicators warrants careful monitoring.
Bollinger Bands analysis shows BNB positioned at 0.63 relative to the bands, trading above the middle band ($619.66) but below the upper resistance at $649.02. The Average True Range of $25.81 indicates significant volatility, creating both opportunity and risk for traders.
Key moving averages paint a concerning longer-term picture. While BNB trades above short-term EMAs (EMA 12: $620.67), it remains significantly below the SMA 50 ($764.10) and SMA 200 ($904.34), indicating the broader trend remains bearish despite recent recovery attempts.
Binance Coin Price Targets: Bull vs Bear Case Bullish Scenario The immediate resistance cluster between $647-$667 represents the first major test for BNB bulls. A decisive break above $647.68 could trigger momentum toward the strong resistance at $667.88.
Technical confirmation would require: - RSI breaking above 50 with sustained momentum - MACD histogram turning positive - Volume expansion on breakout attempts
Success at $667 resistance could open the door to retesting the $700-$750 zone, though this appears optimistic given current market structure.
Bearish Scenario Failure to hold above the pivot point at $620.34 could trigger selling pressure toward immediate support at $600.14. A break of this level would likely accelerate declines toward the critical $572.80 support zone.
Bears would target: - Initial test of $600 support - Break toward $572.80 strong support - Potential decline to $550-$500 if broader crypto markets weaken
The significant gap between current price and longer-term moving averages suggests substantial overhead resistance in any sustained rally attempt.
Should You Buy BNB? Entry Strategy Conservative traders should wait for a clear break above $647 resistance with volume confirmation before establishing long positions. The current $627 level offers limited risk/reward given proximity to resistance.
More aggressive traders might consider: - Partial positions on dips toward $600-$610 support - Stop-loss below $590 to limit downside risk - Taking profits at $650-$660 resistance cluster
Risk management remains crucial given BNB's elevated volatility. Position sizing should account for the $25+ daily ATR, which could easily trigger stop-losses in normal market fluctuations.
Conclusion This BNB price prediction suggests a cautiously neutral outlook for Binance Coin in the near term. While recent 5.46% gains provide short-term optimism, the technical structure indicates BNB remains in a broader downtrend despite oversold bounces.
The most likely scenario sees BNB testing resistance between $647-$667 over the next week, with success determining whether the token can mount a more significant recovery. However, failure at these levels could quickly return focus to downside targets near $572.
Traders should approach BNB with measured expectations, as the Binance Coin forecast suggests choppy price action likely continues until clearer directional momentum emerges in broader cryptocurrency markets.
Disclaimer: Cryptocurrency price predictions are highly speculative and subject to extreme volatility. This analysis is for informational purposes only and should not be considered financial advice. Always conduct your own research and risk assessment before making investment decisions.
Image source: Shutterstock
bnb price analysis bnb price prediction
2026-02-26 07:1617d ago
2026-02-26 00:4117d ago
XRP Price Prediction: Targets $2.50-$3.50 by Late 2026
XRP trades at $1.45 with neutral RSI at 45.26. Technical analysis points to $2.50-$3.50 targets by late 2026, requiring break above $1.57 resistance for bullish confirmation.
What Crypto Analysts Are Saying About Ripple Recent analyst forecasts present an optimistic outlook for XRP's trajectory through 2026. DeepSeek AI released a prediction on February 25, 2026, stating that "given the severity of the crash that the cryptocurrency had already experienced, the AI estimated a rally through the middle and the second half of 2026 is highly likely. Therefore, it sets its XRP price target for the end of 2026 at $2.80 – 102% above the token's press time price of $1.38."
Forbes provided a more detailed scenario-based Ripple forecast on February 20, 2026, suggesting that with "one or two corridors live, regulatory clarity improves — $2.50 to $4.00. Real on-chain volume begins to emerge, ETF inflows build steadily, and institutional interest formalizes. A breakout and sustained hold above $3.30–$3.60 would signal the market is pricing in durable demand rather than a sentiment rally."
Additionally, AOL reported on February 19, 2026, that "ChatGPT forecasts XRP at $2.50 to $3.50 by late 2026, implying up to 155% upside from current levels near $1.45."
XRP Technical Analysis Breakdown XRP currently trades at $1.45, showing a solid 5.90% gain over the past 24 hours within a trading range of $1.36 to $1.49. The technical landscape presents a mixed but gradually improving picture for this XRP price prediction.
The Relative Strength Index sits at 45.26, placing XRP in neutral territory with room for upward movement before reaching overbought conditions. This neutral RSI reading suggests that XRP hasn't yet attracted excessive buying pressure, potentially leaving space for sustainable price appreciation.
MACD indicators show bearish momentum with a histogram reading of 0.0000, though the convergence between MACD (-0.0705) and its signal line (-0.0705) suggests the bearish trend may be losing steam. The Stochastic oscillator shows %K at 37.41 and %D at 29.93, both in oversold territory, which could indicate a potential reversal opportunity.
Bollinger Bands analysis reveals XRP trading at 0.64 within the bands, closer to the upper band ($1.51) than the lower band ($1.34). The middle band sits at $1.42, closely aligned with current price action. This positioning suggests XRP has room to test the upper band resistance.
Key technical levels show immediate resistance at $1.51 and strong resistance at $1.57, while immediate support lies at $1.37 with strong support at $1.30. The Average True Range of $0.09 indicates moderate volatility, providing opportunities for both swing traders and long-term investors.
Ripple Price Targets: Bull vs Bear Case Bullish Scenario The optimistic case for this XRP price prediction centers on breaking above the $1.57 strong resistance level. A sustained move above this threshold would likely target the 50-day SMA at $1.69, representing a 16.5% upside from current levels.
Beyond the near-term technical targets, the confluence of analyst predictions pointing to $2.50-$3.50 by late 2026 suggests significant upside potential. The bullish scenario requires XRP to reclaim and hold above key moving averages, particularly the 20-day SMA at $1.42, which currently provides modest support.
A break above $1.69 would open the path toward the 200-day SMA at $2.30, aligning with the more conservative end of analyst forecasts. For the highest targets around $3.50-$4.00 to materialize, XRP would need sustained institutional adoption and regulatory clarity as outlined in the Forbes analysis.
Bearish Scenario The bearish case for XRP involves a failure to hold current support levels. Immediate downside risk emerges if XRP breaks below $1.37 support, which could trigger selling toward the strong support zone at $1.30.
A breakdown below $1.30 would invalidate the current consolidation pattern and potentially lead to a retest of lower levels. The bearish momentum indicated by the MACD histogram at 0.0000 suggests limited buying pressure, making XRP vulnerable to broader market weakness.
The significant gap between current price ($1.45) and the 200-day SMA ($2.30) highlights the technical damage from previous declines, requiring substantial fundamental catalysts to bridge this divide for any Ripple forecast to reach analyst targets.
Should You Buy XRP? Entry Strategy Based on current technical conditions, potential XRP buyers should consider a layered approach. The immediate entry opportunity exists around current levels of $1.45, with a stop-loss positioned below the strong support at $1.30 to limit downside risk to approximately 10%.
A more conservative entry strategy involves waiting for a clear break above $1.57 resistance with volume confirmation before initiating positions. This approach reduces risk but may result in missing the initial move.
For risk management, consider position sizing that accommodates the daily ATR of $0.09, allowing for normal volatility while maintaining stop-loss discipline. The neutral RSI reading provides flexibility for both immediate entry and waiting for better technical confirmation.
Dollar-cost averaging into XRP positions over the coming weeks could prove effective, particularly if the price consolidates within the current $1.30-$1.57 range while building momentum for the predicted longer-term targets.
Conclusion This XRP price prediction suggests cautious optimism for Ripple's prospects through 2026. While near-term technical indicators present a mixed picture, the convergence of multiple analyst forecasts pointing to $2.50-$3.50 targets provides a compelling case for patient investors.
The key technical level to watch remains $1.57 resistance. A clean break above this level with sustained volume would validate the bullish thesis and potentially accelerate movement toward the $1.69-$2.30 range. However, failure to hold current support levels could extend the consolidation phase and delay the achievement of higher targets.
Disclaimer: Cryptocurrency price predictions are speculative and based on technical analysis and market sentiment. Past performance does not guarantee future results. Always conduct your own research and consider your risk tolerance before making investment decisions.
Image source: Shutterstock
xrp price analysis xrp price prediction
2026-02-26 07:1617d ago
2026-02-26 00:4317d ago
WLFI proposes governance staking system and USD1 usage incentives
Trump family-backed crypto venture World Liberty Financial (WLFI) has proposed new measures to boost participation in governance through a staking system and incentivize the use of its stablecoin USD1.
In its latest proposal on Wednesday, the team suggested governance votes should require holders to stake their tokens for at least 180 days to ensure “voting power is held by participants with long-term alignment to the protocol,” instead of “short-term holders or speculators.”
Stakers would earn an annual percentage rate of 2% provided they participate in at least two governance votes during the lock-up period. Governance power would be based on the amount staked and the time left in the lock-up. Users with locked tokens can continue to vote as usual.
Source: World Liberty FinancialIncentives for USD1 usage on the table too WLFI has been trying to increase USD1 adoption since it launched through rewards programs and partnerships with institutional platforms and other protocols.
As part of the staking system, the WLFI team said users who stake their tokens would also gain “additional benefits for USD1 usage,” with USD1 deposits made on the trading and lending platform WLFI Markets attracting unspecified “incentives” from the DeFi protocol Dolomite.
At the same time, “Nodes,” holders with at least 10 million WLFI tokens, will gain access to providers who offer conversion of other stablecoins like USDC (USDC) and USDt (USDT) into USD1 at a 1:1 rate and can provide an off-ramp directly to fiat.
“Super Nodes,” or holders with more than 50 million WLFI tokens, will also have access to the feature.
World Liberty Financial is offering incentives for token holders to stake and participate in governance decisions. Source: World Liberty Financial For the vote to be valid, the WLFI team has set the bar at one billion voting tokens participating, with a majority voting in favor required for it to pass. CoinGecko lists over 27 billion WLFI tokens in circulation.
If approved, the rollout will be in three phases: starting with staking rewards and USD1 deposit incentives, followed by the 1:1 conversion feature and lastly partnership access and a revenue-sharing framework for “Super Nodes.”
Stablecoin market dominated by USDC and USDTThe total market capitalization for stablecoins is over $309 billion as of Thursday, according to DeFi aggregator DefiLlama. USDT has the largest market cap with over $183 billion and a market dominance of 59%.
Circle’s USDC is the second-largest stablecoin by market cap, with $75 billion. WLFI’s USD1 is the fifth-largest stablecoin with a $4.7 billion market cap.
Magazine: Bitcoin’s ‘biggest bull catalyst’ would be Saylor’s liquidation: Santiment founder
Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy
2026-02-26 07:1617d ago
2026-02-26 00:4517d ago
Indiana's bitcoin rights bill heads for final sign-off after bicameral approval
Cardano trades at $0.29 with bullish signals emerging. Technical analysis suggests ADA could target $0.34 resistance within 2-4 weeks if current momentum sustains.
What Crypto Analysts Are Saying About Cardano Recent analyst commentary on Cardano remains limited, though Timothy Morano provided a notable ADA price prediction in early January, suggesting "upside to $0.48-$0.55 range within 4 weeks as bullish MACD momentum builds, with critical resistance break at $0.43 needed."
While specific analyst predictions from major crypto influencers are sparse, on-chain metrics and technical indicators suggest Cardano is positioning for a potential breakout. According to technical analysis platforms, ADA's current positioning near Bollinger Band resistance indicates growing buying pressure that could catalyze further upside movement.
ADA Technical Analysis Breakdown Cardano's technical picture presents a mixed but increasingly bullish outlook. Trading at $0.29, ADA has demonstrated impressive strength with a 10.75% gain in the past 24 hours, breaking above its 7-day and 20-day moving averages of $0.28.
The RSI reading of 51.46 places ADA in neutral territory, providing room for additional upside without entering overbought conditions. However, the MACD histogram at 0.0000 suggests bearish momentum is waning, potentially setting the stage for a bullish crossover.
Most notably, Cardano's Bollinger Band position at 0.90 indicates the price is trading near the upper band resistance at $0.30. This positioning, combined with increased trading volume of $96.6 million on Binance, suggests accumulation and potential breakout momentum.
The Stochastic oscillator shows %K at 66.83 and %D at 53.47, indicating upward momentum that hasn't yet reached overbought levels. This technical configuration supports the case for continued near-term strength.
Cardano Price Targets: Bull vs Bear Case Bullish Scenario If ADA maintains current momentum and breaks through immediate resistance at $0.32, the next major target sits at $0.34 - representing the strong resistance level identified in technical analysis. A successful break above $0.34 could open the door to Morano's suggested $0.48-$0.55 range within the coming month.
Key technical confirmation would come from: - MACD histogram turning positive - Sustained trading above the 20-day moving average - Volume expansion on breakout attempts
Bearish Scenario Failure to hold above current support levels could see ADA retreat toward $0.27 (immediate support) and potentially $0.24 (strong support). The significant gap between current price ($0.29) and the 50-day moving average ($0.32) suggests overhead resistance remains substantial.
Risk factors include: - Broader crypto market weakness - Failed breakout attempts leading to profit-taking - MACD remaining in bearish territory
Should You Buy ADA? Entry Strategy For traders considering ADA positions, the current technical setup suggests a measured approach. The ideal entry strategy would involve:
Conservative Entry: Wait for a pullback to $0.27-$0.28 support levels with confirmed buying interest Aggressive Entry: Current levels around $0.29 with a tight stop-loss below $0.27 Breakout Play: Entry above $0.32 with volume confirmation, targeting $0.34
Risk management is crucial given ADA's daily ATR of $0.02, suggesting normal volatility could result in 7% daily moves. A stop-loss below $0.24 (strong support) would limit downside risk while allowing room for normal price fluctuations.
Conclusion This Cardano forecast suggests ADA is positioned for potential upside over the next 2-4 weeks, with technical indicators showing improving momentum despite mixed signals. The ADA price prediction of $0.34 represents a reasonable 17% upside target from current levels, supported by resistance/support analysis and analyst projections.
However, investors should note that cryptocurrency price predictions carry significant uncertainty. While technical analysis provides valuable insights, external factors including market sentiment, regulatory developments, and Bitcoin's direction will heavily influence Cardano's actual performance.
Confidence Level: Moderate (60%) - based on improving technicals but limited fundamental catalysts
Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Cryptocurrency investments carry substantial risk, and past performance does not guarantee future results.
Image source: Shutterstock
ada price analysis ada price prediction
2026-02-26 07:1617d ago
2026-02-26 00:5117d ago
Bitcoin Hits $70K Before Sharp Pullback as Altcoins Steal Show
Bitcoin touched $70,000 on February 26. The milestone came fast but didn’t last long, with the cryptocurrency retreating within hours as traders shifted focus to alternative digital assets that were posting bigger gains.
Ether jumped hard that day, outpacing Bitcoin’s performance by a wide margin. Solana and Cardano also saw notable rallies, pretty much capturing all the attention from investors who wanted exposure to riskier crypto plays. The altcoin surge happened despite Bitcoin’s brief peak, showing how quickly sentiment can shift in these markets. Trading volumes across major exchanges spiked for these alternative tokens, with many platforms reporting their busiest altcoin trading days in months.
Market analysts cleared up one thing. The forced selling from early February was done.
But Bitcoin’s retreat from $70,000 left room for altcoins to run. Traders didn’t seem too worried about the broader market turbulence – they just moved money around. Ethereum saw particularly strong demand, with futures trading volumes jumping 30% on FTX alone, according to exchange data.
Binance reported notable increases in Solana and Cardano trading volumes on February 26. Both tokens grabbed investor attention while Bitcoin struggled to hold its gains. The exchange saw trading patterns shift dramatically throughout the day, with altcoin activity dominating the platform’s busiest trading hours. Solana’s volume doubled compared to the previous week on Bitfinex, suggesting traders were betting big on its continued growth.
Coinbase’s Chief Economist Alice Smith weighed in on the action. She said: “The recent market dynamics reflect a strong appetite for higher-risk assets right now.” Smith pointed out that altcoins often see sharper price swings, which attracts traders looking for quick profits. Her comments came as Ether trading volume on Kraken surged 25% compared to the week before.
Things shift fast in crypto.
Cameron Winklevoss from Gemini talked about the altcoin resilience during Bitcoin’s wobbly moments. He said: “The current environment presents unique opportunities for altcoins to shine as traders diversify their holdings.” His remarks lined up with what exchanges were seeing – money flowing out of Bitcoin positions and into alternative cryptocurrencies across the board. More on this topic: Altcoin Bloodbath Hits 9 Billion as.
OKX saw a 40% jump in Cardano transactions on February 26, driven by new users joining the platform specifically to trade that token. The exchange noted that Cardano’s expanding ecosystem and recent partnerships were drawing fresh investor interest. Platform data showed many of these new users were coming from traditional finance backgrounds, suggesting institutional interest was building.
Crypto exchanges across the industry reported similar patterns. The shift away from Bitcoin dominance became pretty clear as altcoin transaction volumes climbed throughout the day. Traders seemed focused on capturing potential profits from digital assets that weren’t Bitcoin, basically betting that these alternative tokens would continue outperforming.
Despite Bitcoin’s temporary $70,000 peak, the cryptocurrency faces ongoing challenges to its market dominance. Altcoins have been gaining ground for weeks now, and that trend accelerated on February 26. The diversification into other tokens shows how investors are searching for better opportunities beyond the original cryptocurrency.
Bitcoin’s pullback from $70,000 highlights just how volatile these markets remain. Altcoins capitalized on the instability, attracting more interest from both retail and institutional traders. The crypto market stays unpredictable, with sudden shifts in investor strategies happening almost daily.
Ethereum, Solana, and Cardano’s performance on February 26 really showed the appeal of altcoins right now. These tokens have become attractive alternatives for traders who want exposure to crypto but aren’t convinced Bitcoin will lead the next rally. Their surge points to a dynamic market environment where risk appetite drives most trading decisions.
Major Bitcoin investors haven’t commented publicly on the altcoin rally yet. The lack of response leaves market participants guessing about potential strategic shifts from big players. Any statements from whale investors or institutional holders could influence market perceptions and trading behaviors going forward. More on this topic: Bitcoin Developer Pushes Discord to Ditch.
The crypto landscape keeps shifting as investors get drawn to altcoins while Bitcoin struggles. Trading patterns on February 26 highlighted evolving preferences among traders who are eager to navigate volatile markets effectively. Exchange data suggests this trend might continue if altcoins keep offering compelling returns compared to Bitcoin.
For now, altcoins are stealing the show with their robust performance. Their rise suggests a potential recalibration of investor priorities, with many traders viewing alternative cryptocurrencies as better bets than Bitcoin. The broader crypto market adjusts rapidly to new realities, and February 26 marked another clear example of how quickly sentiment can change.
Future developments remain uncertain as regulatory actions, technological advances, and market sentiment will influence trends. As altcoins gain ground, their role in the broader crypto ecosystem could expand significantly. Market participants are watching closely for further price movements and strategic investments from major players.
Regulatory uncertainty continues weighing on Bitcoin adoption, with the SEC’s delayed decisions on spot ETF applications creating additional headwinds for the flagship cryptocurrency. Meanwhile, Ethereum benefits from clearer regulatory frameworks around its proof-of-stake transition, giving institutional investors more confidence in alternative digital assets.
The February 26 trading patterns mirror broader institutional shifts toward diversified crypto portfolios. Goldman Sachs recently expanded its digital asset trading desk to include more altcoins, while JPMorgan’s blockchain division increased research coverage on Ethereum-based projects. These moves signal growing Wall Street interest in cryptocurrencies beyond Bitcoin.
Post Views: 13
2026-02-26 07:1617d ago
2026-02-26 00:5317d ago
SOL Price Prediction: Solana Targets $97 Resistance Amid Technical Recovery
What Crypto Analysts Are Saying About Solana While specific analyst predictions from key opinion leaders are limited in recent trading sessions, institutional forecasts remain optimistic for Solana's trajectory. InvestingHaven recently noted that "Solana's bullish cup and handle pattern is forecasted to resolve higher" with SOL confirming "predicted support around $111." Their analysis suggests "SOL max price targets for 2026 are in the $255 to $480 range."
CoinPriceForecast maintains a more conservative outlook, projecting "the forecasted Solana price at the end of 2026 is $156.64."
According to on-chain data from major exchanges, SOL has demonstrated resilience above key technical levels, with trading volume reaching $469.4 million on Binance spot markets alone, indicating strong institutional interest.
SOL Technical Analysis Breakdown Solana's current technical setup presents a mixed but increasingly bullish picture. Trading at $87.65, SOL has gained 7.55% in the past 24 hours, breaking above several key moving averages.
The RSI reading of 45.93 positions SOL in neutral territory, providing room for upward movement without entering overbought conditions. This Solana forecast suggests potential for continued momentum without immediate reversal pressure.
MACD analysis reveals bearish momentum is weakening, with the histogram at 0.0000, indicating a potential shift in trend direction. The convergence between MACD lines suggests momentum could turn bullish in the near term.
Bollinger Band analysis shows SOL trading at 77% of the band range, closer to the upper band at $90.64 than the lower band at $77.51. This positioning indicates building bullish pressure as SOL approaches resistance levels.
Key moving averages paint a recovery story: SOL trades above the 7-day SMA ($83.60) and 20-day SMA ($84.07), though remains below the 50-day SMA ($108.03) and 200-day SMA ($158.48), indicating medium-term resistance ahead.
Solana Price Targets: Bull vs Bear Case Bullish Scenario In the bullish case, SOL price prediction models target the immediate resistance at $92.69 as the first hurdle. A decisive break above this level with volume confirmation could propel Solana toward the strong resistance zone at $97.73.
Technical confirmation would require RSI breaking above 50 and MACD histogram turning positive. The daily ATR of $5.12 suggests SOL has sufficient volatility to achieve these targets within a 7-10 day timeframe.
Extended bullish targets align with the 50-day moving average at $108.03, representing a 23% upside from current levels. This Solana forecast would require broader crypto market support and sustained buying pressure.
Bearish Scenario The bearish scenario focuses on the immediate support at $82.02. A breakdown below this level could trigger selling toward the strong support zone at $76.39, representing a 13% downside risk.
Critical risk factors include MACD remaining in negative territory and failure to reclaim the Bollinger Band middle line at $84.07 on a sustained basis. The 24-hour low at $81.43 serves as a crucial floor for the current recovery attempt.
Should You Buy SOL? Entry Strategy For traders considering SOL positions, the current technical setup offers defined entry and exit points. Conservative buyers should wait for a pullback to the $84-85 range, near the 20-day moving average, which has provided recent support.
Aggressive traders might consider entries on breaks above $90.64 (upper Bollinger Band) with tight stops below $87. This approach captures momentum but carries higher risk.
Stop-loss placement should consider the daily ATR of $5.12. Setting stops 1.5x ATR below entry points ($7.68) provides room for normal volatility while protecting capital.
Position sizing should account for SOL's elevated volatility, with maximum risk of 1-2% of portfolio value per trade.
Conclusion The SOL price prediction for the coming week favors a bullish bias, with targets at $92-97 appearing achievable based on current technical momentum. The 7.55% daily gain demonstrates renewed interest in Solana, while neutral RSI readings suggest room for further appreciation.
However, traders should remain cautious given SOL's position below longer-term moving averages. The medium-term Solana forecast depends on broader crypto market conditions and SOL's ability to sustain trading above $87 support.
Disclaimer: Cryptocurrency price predictions involve significant risk. Past performance does not guarantee future results. Always conduct your own research and consider your risk tolerance before trading.
Image source: Shutterstock
sol price analysis sol price prediction
2026-02-26 07:1617d ago
2026-02-26 00:5517d ago
World Liberty Financial proposes new staking-focused governance system for WLFI holders
The crypto market turned positive over the past 24 hours, with broad participation across major assets and legacy altcoins. Total market capitalisation rose fro $2.19 trillion to $2.35 trillion as Bitcoin price stabilized above $68,000, and established tokens like Polkadot (DOT), Uniswap (UNI), and Cardano (ADA) posted notable gains.
Dogecoin trades at $0.10 with neutral RSI and bearish MACD momentum. Technical analysis suggests DOGE could target $0.115 on breakout above $0.11 resistance or fall to $0.09 support.
What Crypto Analysts Are Saying About Dogecoin While specific analyst predictions are limited in recent trading sessions, on-chain metrics and historical data patterns provide insights into DOGE's potential trajectory. According to available market data, Dogecoin has shown resilience around current levels with significant trading volume of $147.5 million on Binance spot markets over the past 24 hours.
Recent analysis from blockchain data platforms suggests that DOGE's current positioning near psychological support levels could present both opportunity and risk for traders. The meme coin's 8.34% gain in the last 24 hours indicates renewed interest, though technical indicators remain mixed.
DOGE Technical Analysis Breakdown Dogecoin's technical picture presents a neutral-to-bearish setup with several key indicators worth monitoring. The RSI sits at 47.36, placing DOGE in neutral territory with neither overbought nor oversold conditions present. This suggests the current price action lacks strong directional momentum.
The MACD analysis reveals concerning signals for bulls. With the MACD at -0.0039 and the MACD signal also at -0.0039, the histogram reading of 0.0000 indicates bearish momentum remains intact. This divergence suggests selling pressure could persist in the near term.
Bollinger Bands provide additional context for the DOGE price prediction. Trading at 62% of the Bollinger Band range (0.6221 %B position), Dogecoin sits closer to the upper band ($0.11) than the lower band ($0.09), indicating recent strength despite underlying bearish momentum. The middle band aligns with the 20-day SMA at $0.10, serving as a critical pivot point.
Moving averages paint a mixed picture across timeframes. Short-term EMAs (12 and 26-period) both sit at $0.10, matching current price levels. However, the longer-term perspective shows weakness, with the 200-day SMA at $0.17 significantly above current trading ranges, highlighting the substantial distance DOGE must cover to regain longer-term bullish momentum.
Dogecoin Price Targets: Bull vs Bear Case Bullish Scenario The optimistic Dogecoin forecast hinges on a decisive break above the $0.11 resistance level. This level represents both the immediate resistance and the upper Bollinger Band, making it a critical technical barrier. A sustained move above $0.11 with strong volume could target the $0.115 level, representing a 15% gain from current prices.
For this bullish scenario to materialize, DOGE would need to see the RSI push above 50 into bullish territory while the MACD histogram turns positive. The 24-hour trading range high of $0.11 has already been tested, so bulls need to demonstrate conviction with a clean breakout accompanied by volume expansion.
Bearish Scenario The bearish case for this DOGE price prediction centers on the failure to break $0.11 resistance and subsequent weakness below the $0.10 pivot. Current MACD bearish momentum supports this scenario, with the immediate support at $0.09 serving as the first downside target.
A break below $0.09 would likely accelerate selling toward stronger support levels. The daily ATR of $0.01 suggests relatively contained volatility, but a breakdown could see DOGE testing levels significantly below current ranges. Bears would target psychological support zones with potential for further weakness if broader crypto markets experience selling pressure.
Should You Buy DOGE? Entry Strategy For traders considering DOGE positions, the current technical setup suggests waiting for clearer directional signals. Conservative bulls might consider entries on a confirmed break above $0.11 with stop-losses below $0.10. This approach limits risk while positioning for potential upside toward $0.115.
Alternatively, value-oriented investors could consider accumulation near the $0.09 support level, using tight stops below this zone. This strategy offers better risk-reward ratios but requires patience for price to reach these lower levels.
Risk management remains crucial given the mixed technical signals. Position sizing should account for DOGE's historical volatility and the broader cryptocurrency market's unpredictable nature. The neutral RSI provides flexibility for both bullish and bearish moves, making position timing critical.
Conclusion This Dogecoin forecast suggests DOGE faces a critical juncture at current levels. While the 8.34% daily gain shows renewed interest, underlying technical indicators present mixed signals that warrant caution. The most probable near-term scenario involves continued consolidation between $0.09 and $0.11 until a clear directional catalyst emerges.
Traders should monitor the $0.11 resistance level closely, as a decisive break could trigger the bullish scenario targeting $0.115. Conversely, failure to maintain current levels might see DOGE test $0.09 support. Given the neutral RSI and bearish MACD momentum, maintaining a balanced approach with proper risk management appears prudent.
Disclaimer: Cryptocurrency price predictions are highly speculative and subject to extreme volatility. This analysis is for informational purposes only and should not be considered financial advice. Always conduct your own research and consider your risk tolerance before making investment decisions.
Image source: Shutterstock
doge price analysis doge price prediction
2026-02-26 07:1617d ago
2026-02-26 01:0017d ago
Ethereum Exchange Deposits Hit A Six-Month High: Panic Selling Or Structural Reset?
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure
Ethereum continues to face sustained selling pressure as broader crypto market sentiment shifts toward caution and, in some segments, outright panic. Price action has struggled to regain stability in recent weeks, with repeated rebound attempts failing to produce sustained upside momentum. Elevated volatility, tightening liquidity conditions, and persistent macro uncertainty have reinforced a defensive posture among both retail and institutional participants, leaving Ethereum vulnerable to further short-term weakness.
A recent CryptoQuant report provides additional context through on-chain activity. According to the data, the ETH Binance User Deposit Address metric has recorded a sharp increase. The number of unique addresses depositing Ethereum to Binance has surged from roughly 360,000 to more than 450,000, representing the highest level observed since August 2025. Metrics tracking deposit addresses often serve as a proxy for potential sell-side intent, since assets transferred to exchanges are typically more accessible for liquidation, collateral usage, or portfolio rebalancing.
However, such spikes do not automatically translate into immediate selling. In some cases, they reflect positioning adjustments, hedging activity, or preparation for derivatives trading. Even so, the scale of the recent increase suggests heightened market anxiety and warrants close monitoring as Ethereum navigates an increasingly fragile market environment.
Exchange Deposits Surge As Price Correction Deepens The report highlights that this metric breakout has occurred alongside a severe price correction. Ethereum has declined sharply from its October peak near $4,900 to roughly the $1,900 region. The simultaneous drop in price and surge in exchange deposit addresses suggests two primary on-chain interpretations that merit careful consideration.
Ethereum Binance User Deposit Address | Source: CryptoQuant The first scenario points to retail capitulation. A rapid increase in unique depositing addresses often reflects panic behavior among smaller investors. Participants who held through earlier stages of the decline may now be transferring assets to exchanges to exit positions, reinforcing short-term sell-side pressure.
The second interpretation relates to derivatives market positioning. With ETH trading below the $2,000 threshold, some deposits likely represent collateral replenishment. Traders facing liquidation risk may be adding margin to maintain leveraged long positions rather than outright selling their holdings.
In the near term, increased deposits elevate potential supply on exchanges, which can intensify volatility if selling materializes. However, historically, extreme spikes in deposit activity have frequently appeared during late-stage corrective phases. Such conditions sometimes precede seller exhaustion.
Monitoring exchange outflows, spot volume absorption, and derivatives positioning will be critical to determine whether this activity signals continued downside risk or the early formation of a local market bottom.
Ethereum Tests Structural Support As Downtrend Persists Ethereum continues to trade under sustained pressure, with the weekly chart showing a clear loss of bullish momentum following the rejection near the $4,800–$5,000 region. Price has now retraced toward the $1,900 area, a zone that previously acted as consolidation support during earlier cycle phases. The inability to hold above the mid-cycle moving averages suggests that sellers still maintain structural control.
ETH testing critical price level | Source: ETHUSDT chart on TradingView The 50-week moving average has rolled over and now acts as overhead resistance, while the 100-week average appears to be flattening. Meanwhile, price is approaching the longer-term 200-week moving average, a level historically associated with major cyclical support. A decisive breakdown below this region could expose deeper downside, whereas stabilization here may encourage medium-term accumulation.
Volume patterns indicate intermittent spikes during declines, which typically reflect distribution rather than sustained buying interest. This reinforces the interpretation of a defensive market phase rather than a confirmed recovery trend.
Despite the weakness, volatility compression near long-term averages sometimes precedes transitional periods. Confirmation, however, would require sustained closes above reclaimable resistance levels and improving participation metrics. Until then, Ethereum remains in a fragile technical posture with risk skewed toward continued consolidation or downside drift rather than immediate bullish continuation.
Featured image from ChatGPT, chart from TradingView.com
Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.
2026-02-26 07:1617d ago
2026-02-26 01:0017d ago
Bitcoin Yet To See Meaningful Capital Return, Glassnode Says
On-chain analytics firm Glassnode has highlighted how accumulation from the large Bitcoin entities has remained relatively weak recently.
Bitcoin Accumulation Trend Score Has Been Struggling To Break 0.5 In a new post on X, Glassnode has talked about the latest trend in the Accumulation Trend Score for Bitcoin. This on-chain indicator tracks whether BTCinvestors are accumulating or distributing right now. The metric calculates its value by looking at the balance changes happening in the wallets of the investors. Additionally, it also accounts for the size of the wallets themselves. This second weighting factor means that larger entities have a stronger influence on the indicator.
When the value of the Accumulation Trend Score is greater than 0.5, it means large investors (or a large number of small entities) are accumulating. The closer the metric is to 1, the stronger this behavior is. On the other hand, the indicator being under 0.5 implies that distribution is the dominant behavior on the network. The extreme point on this side of the scale lies at 0.
Now, here is the chart shared by Glassnode that shows how the Bitcoin Accumulation Trend Score has changed over the course of the cycle:
Accumulation demand has remained weak in the market recently | Source: Glassnode on X As displayed in the above graph, the Bitcoin price crash in November saw the Accumulation Trend Score take on a dark purple color. Here, a light yellow shade on the indicator reflects a value close to zero, while a dark purple one to a value near 1. Thus, it would appear that the market reacted with a near-perfect accumulation behavior to the November price lows.
While December saw continued accumulation, a shift occurred in January; the price recovery rally was met with distribution as the Accumulation Trend Score turned orange-yellow. The cryptocurrency’s price has plummeted since the onset of this selling pressure.
The price crash has been met with some accumulation, but from the chart, it’s visible that the indicator’s color has still only been red. “The Accumulation Trend Score has struggled to push above 0.5 since early February,” noted the analytics firm.
While the current value suggests aggressive distribution is no longer happening, it’s not necessarily a sign of a return of demand for Bitcoin, either. As Glassnode explained, the trend reflects “persistently weak accumulation, particularly among larger entities, signalling that meaningful capital has yet to step back in.” It now remains to be seen how long the current neutral market behavior will continue and which way the next shift will lean.
BTC Price Bitcoin slipped under the $63,000 level on Tuesday, but the market has rebounded since then as the cryptocurrency’s price has returned to $65,300.
The trend in the price of the coin over the last five days | Source: BTCUSDT on TradingView Featured image from Dall-E, chart from TradingView.com
2026-02-26 07:1617d ago
2026-02-26 01:0517d ago
MATIC Price Prediction: Polygon Eyes $0.45-$0.52 Recovery Target as Technical Indicators Signal Mixed Momentum
MATIC trades at $0.38 with neutral RSI and bearish MACD. Analysts target $0.45-$0.52 upside if key resistance breaks, though current momentum remains cautious.
Polygon (MATIC) currently trades at $0.38, down 0.29% in the last 24 hours, as the layer-2 scaling solution faces mixed technical signals. With neutral RSI conditions and bearish momentum indicators, traders are watching key resistance levels that could determine MATIC's next major move.
What Crypto Analysts Are Saying About Polygon Recent analyst commentary provides cautious optimism for MATIC's price trajectory. Felix Pinkston noted on February 18, 2026: "MATIC trades at $0.38 with neutral RSI at 38.00. Technical analysis suggests potential recovery to $0.45-$0.52 range if Polygon breaks key resistance levels in coming weeks."
Supporting this outlook, Luisa Crawford observed on February 21, 2026: "MATIC price prediction shows potential 18-39% upside to $0.45-$0.52 range if bulls break $0.58 resistance, though current technical indicators signal neutral to bearish momentum at $0.38."
These predictions indicate a cautiously optimistic outlook for MATIC, contingent on breaking key resistance levels and maintaining bullish momentum above current support zones.
MATIC Technical Analysis Breakdown Polygon's technical picture presents mixed signals that warrant careful analysis. The RSI currently sits at 38.00, indicating neutral conditions with room for upward movement before reaching overbought territory. This suggests MATIC isn't oversold despite recent weakness.
The MACD tells a more concerning story, with the histogram at -0.0000 and both MACD lines converging at negative values (-0.0246), indicating bearish momentum. However, the extremely tight convergence suggests this bearish pressure may be weakening.
Bollinger Bands analysis reveals MATIC trading near the lower portion of its recent range, with a %B position of 0.29. The current price of $0.38 sits well below the middle band at $0.43, indicating potential for mean reversion higher. The upper band at $0.56 represents a significant resistance level that could trigger the analysts' predicted $0.45-$0.52 target range.
Moving averages paint a mixed picture, with MATIC trading above the 7-day SMA ($0.37) but below all other timeframes. The 20-day SMA at $0.43 represents immediate resistance, while the 50-day at $0.45 aligns with analyst targets.
Polygon Price Targets: Bull vs Bear Case Bullish Scenario In a bullish scenario, MATIC could target the $0.45-$0.52 range as predicted by recent analyst commentary. The path higher would likely see:
Initial resistance at the 20-day SMA ($0.43) Secondary resistance at the 50-day SMA ($0.45) Ultimate target near the upper Bollinger Band ($0.56) For this Polygon forecast to materialize, MATIC would need RSI to break above 50, confirming renewed bullish momentum, and MACD to cross into positive territory. Volume expansion above the current 24-hour average of $1.07 million would provide additional confirmation.
Bearish Scenario The bearish case centers on the lower Bollinger Band at $0.31 as the primary downside target. Key risk factors include:
Failure to reclaim the 20-day SMA ($0.43) MACD histogram declining further into negative territory RSI dropping below 30 into oversold conditions A break below $0.31 could expose MATIC to further downside, potentially testing psychological support levels around $0.25-$0.30.
Should You Buy MATIC? Entry Strategy Based on current technical conditions, a layered entry strategy appears prudent for MATIC price prediction scenarios:
Aggressive Entry: Current levels around $0.38, with a tight stop-loss at $0.35 (below recent support)
Conservative Entry: Wait for a break above $0.43 (20-day SMA) with volume confirmation before entering
Dollar-Cost Averaging: Split entries between $0.35-$0.40 range to capture potential volatility
Risk management remains crucial, with position sizing limited to 1-2% of portfolio given the mixed technical signals and broader market uncertainty affecting layer-2 tokens.
Conclusion MATIC's current technical setup suggests a consolidation phase with potential for the $0.45-$0.52 recovery predicted by analysts, representing 18-37% upside from current levels. However, bearish MACD momentum and position below key moving averages warrant caution.
The Polygon forecast remains conditional on breaking above $0.43 resistance and maintaining support above $0.35. Traders should monitor RSI for signs of momentum shift and volume for confirmation of any breakout attempts.
This MATIC price prediction is for educational purposes only and should not be considered financial advice. Cryptocurrency investments carry significant risk, and past performance does not guarantee future results. Always conduct your own research and consider your risk tolerance before investing.
Image source: Shutterstock
matic price analysis matic price prediction
2026-02-26 07:1617d ago
2026-02-26 01:1117d ago
DOT Price Prediction: Targets $1.83 by March After 27% Rally
Polkadot surges 27% to $1.62, breaking above key moving averages. Technical analysis suggests DOT could reach $1.83 resistance within 2-4 weeks if momentum sustains.
Polkadot (DOT) has delivered an impressive 27.74% surge in the past 24 hours, climbing from $1.26 to $1.62 and breaking above several key technical levels. This dramatic move has shifted the short-term outlook for DOT, with technical indicators now pointing toward potential further upside.
What Crypto Analysts Are Saying About Polkadot Recent analyst sentiment on Polkadot has shown cautious optimism. Felix Pinkston provided a DOT price prediction on February 24, 2026, stating: "DOT Price Prediction Summary: Short-term target (1 week): $1.29; Medium-term forecast (1 month): $1.19-$1.34 range; Bullish breakout level: $1.34; Critical support: $1.19."
Timothy Morano noted on February 21, 2026: "DOT trades at $1.34 with bullish momentum building. Technical analysis suggests potential move to $1.42 resistance, though bears remain in control below key averages."
Notably, DOT has already exceeded both analysts' bullish targets, with the current price of $1.62 representing a significant breakout beyond their projected levels.
DOT Technical Analysis Breakdown The technical picture for Polkadot has dramatically improved following today's rally. DOT is currently trading at $1.62, well above its 7-day SMA ($1.40) and 20-day SMA ($1.35), indicating strong short-term momentum.
RSI Analysis: The 14-period RSI sits at 58.75, placing DOT in neutral territory with room for further upside before reaching overbought conditions above 70.
MACD Signals: While the MACD histogram shows 0.0000, indicating equilibrium between bullish and bearish momentum, the recent price action suggests this could shift positive if the rally continues.
Bollinger Bands: DOT's position at 1.13 relative to the Bollinger Bands indicates the price has moved well above the upper band ($1.57), suggesting strong momentum but also potential for short-term consolidation.
Key Levels: Immediate resistance stands at $1.83, while strong resistance lies at $2.04. Critical support has established at $1.34, with stronger support at $1.05.
Polkadot Price Targets: Bull vs Bear Case Bullish Scenario In the bullish case, DOT could target $1.83 (immediate resistance) within the next 1-2 weeks, representing a 13% gain from current levels. A break above this level could open the door to $2.04 (strong resistance), offering potential upside of 26%.
For this Polkadot forecast to materialize, DOT needs to: - Maintain trading above $1.57 (former upper Bollinger Band) - See RSI push toward 65-70 without becoming severely overbought - Generate sustained volume above the current 24-hour average of $78.2 million
Bearish Scenario The bearish scenario would see DOT retreat to test the $1.34 support level, representing a 17% decline from current prices. A break below this level could trigger further selling toward $1.05 (strong support), implying downside risk of 35%.
Risk factors include: - Failure to hold above the 20-day SMA ($1.35) on any pullback - RSI divergence if price continues higher without momentum confirmation - Broader cryptocurrency market weakness affecting altcoin sentiment
Should You Buy DOT? Entry Strategy For traders considering DOT positions, the current technical setup offers several strategic entry points:
Conservative Entry: Wait for a pullback to $1.45-$1.50 range (near the EMA 26 at $1.45) before entering long positions.
Aggressive Entry: Current levels around $1.62 for those believing in continued momentum, with tight stop-loss at $1.50.
Second target: $1.83 (13% gain) Extended target: $2.04 (26% gain) Conclusion This DOT price prediction suggests Polkadot is positioned for further gains toward $1.83 in the near term, supported by strong technical momentum and a break above key resistance levels. The 27% rally has shifted the technical landscape significantly, with DOT now trading above all short-term moving averages.
However, traders should remain cautious of the extended nature of this move, as the price is currently above the upper Bollinger Band. The Polkadot forecast remains constructive for the next 2-4 weeks, but risk management is essential given the cryptocurrency's volatility.
Disclaimer: Cryptocurrency price predictions are speculative and should not be considered financial advice. Always conduct your own research and consider your risk tolerance before making investment decisions.
Image source: Shutterstock
dot price analysis dot price prediction
2026-02-26 07:1617d ago
2026-02-26 01:2217d ago
Bitcoin gains safeguards as Indiana HB 1042 advances
HB 1042: Allows ETFs, protects self-custody, limits direct tokensIndiana’s legislature has passed HB 1042, a bitcoin rights bill that now awaits Governor Braun’s signature, as reported by The Block (https://www.theblock.co/post/391378/indianas-bitcoin-rights-bill?utm_source=openai). The measure defines guardrails for digital asset access while clarifying privacy and property protections.
The bill would allow regulated cryptocurrency exchange-traded funds in certain public retirement programs, while constraining direct token exposure, particularly in more conservative plan structures. It codifies self-custody protections and limits compelled disclosure of private keys to narrowly tailored court orders when no other legally admissible method exists, according to Indiana House Republicans (https://www.indianahouserepublicans.com/news/press-releases/state-rep.-pierce-introduces-legislation-to-expand-access-to-cryptocurrency-investment-options/?utm_source=openai). Together, those provisions aim to separate diversified, overseen ETF exposure from direct token risks.
Why this matters for pensions and crypto ATM regulationHB 1042 sits at the intersection of retirement policy and consumer protection. For pensions, it could expand choice via regulated ETFs without forcing direct token custody into public plans. For retail users, parallel efforts target cryptocurrency kiosks, a channel associated with fraud against older adults.
Supporters frame the bill as modernization with guardrails rather than speculation. “Insurance for the future of finance,” said Rep. Kyle Pierce (R-Anderson), the bill’s sponsor. He has pointed to regulated ETF on-ramps and privacy protections as central features of the framework.
Advocates for older Hoosiers have focused on fraud prevention at crypto ATMs. AARP Indiana has urged licensing, clear disclosures and warnings, receipts, and transaction limits to mitigate scams that target seniors, emphasizing transparency and recoverability where feasible.
Institutional stakeholders have signaled qualified caution. According to Indiana Capital Chronicle (https://indianacapitalchronicle.com/2026/02/05/indiana-lawmakers-consider-crypto-pension-investments-atm-scam-crackdown/?utm_source=openai), the Indiana Public Retirement System indicated it was broadly comfortable with the negotiated bill language while remaining watchful of ETF risk exposure. The outlet also reported that crypto ATM operators warned fee caps (for example, 10%) and strict transaction limits could render machines uneconomic, especially where cash logistics are costly.
BingX: a trusted exchange delivering real advantages for traders at every level.
If signed, near-term effects would center on implementation planning rather than immediate portfolio shifts. Public retirement programs typically add options through self-directed brokerage features, and fiduciaries would still vet availability, disclosures, and risk controls before any ETF access is offered.
Self-custody and privacy provisions would take effect through the statutory standard: a court could compel private keys only when no other legally admissible means exist. That sets a high bar meant to protect property and due process while preserving investigatory pathways.
On crypto ATMs, the immediate focus is likely compliance design. Proposed licensing, fee or transaction parameters, and mandatory warnings are intended to reduce scam losses, though final thresholds may be adjusted to balance fraud mitigation and operational viability.
At the time of this writing, Bitcoin (BTC) was about $68,289, with sentiment described as bearish, volatility elevated near 9.88%, and a neutral RSI around 42.98. These figures offer market context, not investment guidance.
Key questions on pensions and private key protectionsWill HB 1042 let public pension funds invest in crypto, and is it limited to ETFs?The bill enables access to regulated cryptocurrency ETFs within certain public retirement programs, likely via self-directed brokerage arrangements. Direct token exposure remains constrained, especially for defined benefit plans. Plan fiduciaries would determine implementation details.
How does the bill protect self-custody and private keys, and when could keys be compelled by a court?It protects self-custodied wallets by restricting disclosure of private keys. A court could compel keys only if no other legally admissible method exists. This balances property privacy with evidentiary needs.
HB 1042 awaits the governor’s signature; pension lineup changes, if any, would proceed through standard fiduciary and administrative processes over time.
Crypto ATM proposals emphasize licensing, warnings, receipts, and potential fee or transaction limits to curb scams, while operators warn some caps could make kiosks uneconomic.
DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.
The cryptocurrency market is currently digesting the bombshell lawsuit against Jane Street by the bankruptcy estate of Terraform Labs, which alleges insider trading.
Now, some industry voices are wondering whether or not Jane Street is actually responsible for suppressing the price of the flagship coin.
Jeff Park, advisor at Bitwise, has concluded that the reality is "trickier than the question" and "more structurally unsettling than the conspiracy theory itself."
HOT Stories
According to Park, the alleged price suppression might be a feature of regulatory architecture itself.
The "grey window" of regulationPark has mentioned a specific regulatory exemption within Regulation SHO, a rule designed to govern short selling.
Short sellers typically must "locate" shares before shorting to prevent naked shorting, but Jane Street, JPMorgan, and Goldman Sachs are exempt.
You Might Also Like
"This is the grey window: a regulatory carve-out designed for orderly ETF market-making that is, structurally speaking, indistinguishable from a regulatory arbitrage with unmatched duration," Park wrote.
Suppressing price discovery When an ETF trades below its Net Asset Value (NAV), an arbitrage buyer typically steps in to buy the ETF and sell the underlying asset. In the Bitcoin ETF world, however, the AP is the arb buyer.
Park notes that this breaks the natural mechanism that would typically drive spot buying pressure. "The gap cannot close via the natural arb mechanism because the natural arb buyer chose not to buy spot."
The researcher has concluded that no AP explicitly suppresses the Bitcoin price. However, the AP structure can suppress the integrity of the price discovery mechanism.
Skeptics weigh in Park’s analysis sparked a lot of reactions on social media, and some were skeptical. Dave Weisberger, Co-CEO of CoinRoutes, pushed back on the idea that this suppresses price over the long term.
"Empirically, this isn’t true over any substantial time frame," Weisberger argued. "Futures always resolve to spot on expiration." However, Weisberger acknowledged that manipulation remains a concern.
Keone Hon, CEO of Monad, also challenged the theory. "This conspiracy theory doesn’t hold up," Hon replied. "Hedging short IBIT positions with long futures means that some other party will (on average) end up holding a short futures position that they have to hedge with a long spot position."
2026-02-26 07:1617d ago
2026-02-26 01:3017d ago
FG Nexus Dumps 7,550 ETH as Losses Reach $82 Million
FG Nexus has sold 7,550 ETH, extending a string of liquidations after accumulating more than $196 million worth of ether in 2025. The firm is now sitting on an estimated $82.8 million loss as ETH trades below $2,000.
2026-02-26 07:1617d ago
2026-02-26 01:3417d ago
Pi Network News: One Year Later, Is Pi Quietly Building a Real Blockchain Ecosystem?
Pi Network has completed one year since launching its Open Network, and its founders used the milestone to stress that their focus remains on building infrastructure and real-world use cases rather than chasing short-term price action.
From the very beginning, the project has faced doubt and controversy. Questions about its structure, rollout, and long-term vision have followed it closely, making its first year in the open market anything but quiet.
Pi Co-founder Dr. Nicolas Kokkalis boosts the Pi community with a detailed roadmap of ongoing work on KYC, migration, developer tools, protocol upgrades, and broader ecosystem growth.
While the project’s native token has experienced volatility, the core team continues to push forward with long-term development goals. In a recent video update, Kokkalis laid out how the team is prioritizing work that matters most to Pioneers and builders alike.
“What Pi Is Working On Now”According to Kokkalis, the immediate priorities remain KYC verification and mainnet migration, which he described as fundamental to Pi’s broader vision. He explained that the team is increasing KYC throughput and speeding up verification processes, including “unblocking more users” and integrating advanced technologies like AI into the flow. This, he noted, will help more Pioneers fully participate in the Mainnet ecosystem without unnecessary delays.
“KYC and migration remain a top priority,” Kokkalis said, highlighting that completing identity verification is essential for ensuring the network’s integrity and enabling real usage of Pi tokens. He also mentioned expected KYC validator rewards coming soon, which aim to incentivize community participation and broaden verification coverage.
Building Tools for DevelopersBeyond migration and identity work, Kokkalis stressed the importance of improving developer tools that make it easier to build on Pi’s blockchain.
“We’re lowering the barrier to building on Pi,” he said, noting that new utilities such as faster payment integrations and expanded development environments will help creators launch real applications.
This push aligns with the broader ecosystem’s growth; recent data shows Pi’s Mainnet now supports hundreds of live apps, and over 300 applications are reported running on the network.
Protocol Upgrades and InfrastructureKokkalis also touched on deeper technical work, including upgrades to the network protocol, node infrastructure, and future decentralized exchange (DEX) and liquidity pool components. These upgrades aim to transition Pi from a mobile mining project toward a fully functioning blockchain capable of supporting broad decentralized finance and commerce activity.
Utility Over HypeFounders have repeatedly stressed that Pi’s approach is about utility and real use cases rather than speculation. This philosophy underpins the network’s design choices, from fully KYC-verified participation to ecosystem token models tied to real application usage rather than simple trading.
Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.
Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.
Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.
2026-02-26 07:1617d ago
2026-02-26 01:4717d ago
South Korea arrests two suspects in $1.5M Bitcoin evidence theft
South Korean authorities have arrested two suspects in connection with the theft of 22 bitcoins that had been held as evidence by the Gangnam Police Station, officials announced on Wednesday.
Summary
Two suspects were arrested in South Korea for allegedly stealing 22 bitcoins seized as evidence in a 2021 case. The missing Bitcoin, worth about $1.5 million, was discovered during a nationwide audit of police custody practices triggered by other digital asset losses. Law enforcement plans to implement stronger custody procedures for seized digital assets, including dual custodians and secure storage protocols. Suspects detained as South Korea police probe disappearance of seized Bitcoin The digital assets, seized in November 2021 and valued at roughly ₩2.1 billion (about $1.5 million) at current market prices, were discovered missing during a nationwide audit of law enforcement’s virtual asset custody practices.
The Gyeonggi Northern Provincial Police Agency apprehended the two individuals on February 25, 2026, on suspicion of embezzling the Bitcoin (BTC) after it was held in connection with a criminal investigation that has since been suspended.
The audit was triggered following a separate high-profile incident in which 320 bitcoins went missing from the Gwangju District Prosecutors’ Office custody.
Investigators revealed that while the cold wallet device, a USB-based storage intended to secure the private keys, remained physically in police possession, the bitcoins it contained had been transferred out to an external address without authorization.
Police have not confirmed whether the stolen cryptocurrency has been recovered.
Authorities are tightening procedures for handling seized digital assets. New protocols to be introduced will include assigning dual custodians for wallets and sealing both hardware and recovery phrases, with plans to entrust assets to specialized custodians within the year.
A police official stated that steps will be taken to strengthen safeguards to prevent similar breaches going forward.
The arrests mark a significant escalation in the investigation into internal vulnerabilities related to law enforcement’s management of cryptocurrency evidence, prompting broader scrutiny and calls for overhauled digital asset custody standards.
2026-02-26 07:1617d ago
2026-02-26 02:0017d ago
Liquidity floods Solana as SOL reclaims EMA Ribbon to hit $85 – Details
Solana has started to show strength after a brief period of weakness.
While broader markets struggled, SOL stabilized as bulls stepped back in with conviction. The $75-zone acted as the line in the sand, and buyers defended it aggressively, preventing a deeper breakdown.
This defense signaled that sellers were losing control near support. Therefore, attention shifted towards whether on-chain strength could justify renewed optimism.
At the time of writing, momentum was no longer collapsing. It was rebuilding with intent. This was evident on the price charts, with SOL valued at $88 following a 7% hike in 24 hours.
Solana dominates weekly DEX volume Solana [SOL] commanded trading activity across decentralized exchanges this week.
Top 10 Chains by DEX Volume in the last 7 days showed Solana leading at $15.72 billion. Ethereum followed at $11.64 billion, while BNB Chain trailed at $6.21 billion.
Source: X
Base recorded $5.17 billion, Arbitrum posted $1.87 billion, and Polygon hit figures of $1.48 billion. All while Avalanche logged $999.78M, while Sui and Monad remained below $700M.
The gap was clear and apparent. That may be why liquidity has been so aggressively concentrated on Solana’s network.
Such dominance can also be seen as evidence of active capital rotation, rather than passive speculation.
Are TVL surges a sign of ecosystem acceleration? TVL growth data revealed sharp inflows into select Solana protocols.
SuperstateInc surged 97.23% in 7-day TVL growth. KnightradeTeam followed at 96.42%, nearly matching that explosive pace.
Source: X
The disparity when compared to other pools seemed steep though. dflow hiked by “only” 18.75%, while etherfuse recorded figures of 14.56%. Similarly, other protocols ranged between 3.55% and 14.13%, including HastraFi and solsticefi.
This implied that momentum has been highly concentrated at the top. Also, those near-100% jumps signaled aggressive capital deployment.
Despite the concentration though, growth is undeniable. Needless to say, this has led to renewed conviction inside the ecosystem.
$75 holds as bulls reclaim the EMA ribbon The $75-level held firmly under pressure.
Bulls defended that zone decisively, preventing structural damage. As a result, SOL reclaimed the $80s with authority. More importantly, the price moved back above the EMA ribbon. Therefore, short-term momentum shifted towards buyers.
Source: TradingView
Holding above the EMA ribbon gave bulls leverage. In fact, the RSI showed Solana recovering from the oversold zone. Failure to maintain that position would have invited immediate weakness.
Put simply, technical recovery finally mirrored ecosystem expansion.
Will SOL sustain momentum above the EMA? Now, despite the shift in momentum, sustainability remains the real test. Reclaiming the EMA ribbon altered sentiment quickly. However, at press time, SOL still needed to clear the $90-resistance convincingly.
Solana has the fuel. Looking ahead, consistency matters more than excitement. Should support hold and the $90-level break, momentum could extend further.
Final Summary Solana’s $15.72 billion DEX volume confirmed aggressive liquidity leadership.
Defending $75 and reclaiming the EMA ribbon on the price charts marked a decisive shift for SOL.
2026-02-26 07:1617d ago
2026-02-26 02:0317d ago
Bullish Sentiment Returns as BTC Nears $70K But Is it a Bull Trap?
Crypto market sentiment has been lifted as billions re-enter the space, but could it be a bull trap?
Crypto markets have seen a rare green day with a 3.7% gain in total capitalization, which has increased by around $120 billion to $2.43 trillion.
“Just two days after the crowd was bracing itself with a $60,000 retest, Bitcoin is now on the verge of returning back above $70,000,” commented Santiment on Thursday.
“The bullish narrative has predictably returned,” and the crowd has begun to “flip into FафOMO mode,” it added.
Bitcoin only briefly tapped $70,000 before retreating to $68,000 at the time of writing, so it may have been a bull trap.
🥳 Just 2 days after the crowd was bracing itself with a $60K retest, Bitcoin is now on the verge of returning back above $70K. The bullish narrative has predictably returned. In this chart:
🟦 High blue spikes indicate major predictions of $BTC moving lower. When retail sells,… pic.twitter.com/ymoAhv4GD2
— Santiment (@santimentfeed) February 25, 2026
Bitcoin Bull Trap and Relief Rally “Bitcoin has just entered the final bull trap of this cycle,” said analyst Chiefy, who added that charts are “literally mirroring the 2022 chart right now.” They predicted that BTC would dump to $44,000 in ten days.
A bull trap is a false bullish signal in trading when an asset is in a downtrend, and the price suddenly rallies upward, showing signs of reversal, and luring in bullish traders before the price resumes its downtrend, forcing them to sell. This rise in Bitcoin “is just a relief rally,” said CryptoQuant analyst ‘PelinayPA.’
You may also like: BTC, ETH, XRP Surge as On-Chain Data Shows ‘Explosive Buying’ From Whales Bitcoin’s Dry Powder Myth Busted: Outflows – Not Buyers – Driving Low SSR Coinbase Analysis: Bitcoin Could Slide to This Key Level Before Bounce She pointed out that the Fund Flow Ratio, which measures the amount of BTC flowing into Binance relative to the total held on the exchange, remains at a low level of 0.012.
“A low ratio means fewer BTC are being sent to the exchange. This weakens immediate sell-side supply pressure,” she explained.
This setup may slow the downside momentum and “pave the way for a relief rally,” she added.
“In particular, if the ratio remains low, any upward price reaction could create the conditions for a strong short squeeze. In other words, be prepared for a relief bounce.”
Jane Street Suit Ends Manipulation Analyst ‘Bull Theory’ had a different take. Since Jane Street was sued and manipulation stopped, the crypto market has added over $200 billion in just 48 hours, they said.
“For the first time in two months, no relentless selling has been seen for two consecutive days.”
“Whether it’s Jane Street constantly manipulating the markets,” or the “gamma play on options,” or the correlation with the software companies that have been pushing down Bitcoin prices, “it doesn’t matter,” said MN Fund founder Michaël van de Poppe.
“The current valuation of Bitcoin is extremely low.”
Tags:
2026-02-26 07:1617d ago
2026-02-26 02:1217d ago
Is Jane Street holding Bitcoin below $150K? Jeff Park explains the “grey window” in ETFs
As Bitcoin enthusiasts question why the digital asset hasn’t yet hit the $150,000 milestone despite massive ETF inflows, Jeff Park, Head of Alpha Strategies at Bitwise, has provided a sobering look at the plumbing of the financial system.
Summary
Jeff Park, Head of Alpha Strategies at Bitwise, argues Bitcoin’s failure to hit $150,000 isn’t manipulation but ETF structure. Authorized Participants (APs) can hedge ETF exposure using futures instead of buying spot Bitcoin, weakening the direct link between ETF inflows and price appreciation. The shift to in-kind redemptions and OTC sourcing may reduce public exchange buying pressure, potentially muting Bitcoin’s explosive upside. Bitwise’s Jeff Park says Bitcoin ETFs, not Wall Street, are capping BTC price In a detailed post on X, Park argues that the “villain” isn’t a single firm like Jane Street, but rather the structural architecture of the Bitcoin (BTC) ETF itself.
Everyone is asking: "Is Jane Street why Bitcoin isn't at $150k?"
As expected, the answer is trickier than the question. But it's also more structurally unsettling than the conspiracy theory itself—and once you understand the actual mechanics, you won't be able to unsee them👇 pic.twitter.com/iLEeJpDeo4
— Jeff Park (@dgt10011) February 25, 2026 According to Park, Authorized Participants (APs) operate within a “grey window” of Regulation SHO. While standard traders must locate shares before shorting, APs are exempt due to their role in creating and redeeming ETF shares.
This allows them to maintain positions with a level of capital efficiency and duration that is “indistinguishable from a regulatory arbitrage.”
The most critical revelation involves how these institutions hedge. Typically, an arbitrageur would buy spot Bitcoin to close a price gap.
However, if an AP chooses to hedge using Bitcoin futures instead of the underlying asset, the “spot was never bought.” This breaks the link between ETF demand and spot price appreciation.
Furthermore, the recent transition to “in-kind” redemptions has removed the “structural governor” that previously forced spot buying. APs can now source Bitcoin through private OTC desks with minimal market impact, effectively bypassing the public exchanges where price discovery happens.
Park concludes that while no firm is explicitly “manipulating” the market, the current regulatory framework, designed for traditional assets, is fundamentally at odds with Bitcoin’s mission.
The result is a system where the “middle” of the trade escapes categorization, potentially muffling the explosive price growth investors expected.
Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information
February 26, 2026, 6:30 AM CET
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG).
ADAPT OCULUS met its primary endpoint (p-value=0.012), showing that patients living with oMG and treated with VYVGART demonstrated statistically significant improvement from baseline in Myasthenia Impairment Index (MGII) Patient Reported Outcome (PRO) ocular scores at Week 4 compared to placebo. In the overall population, mean change from baseline in patients treated with VYVGART was a 4.04 point improvement in MGII PRO versus a mean change of 1.99 MGII PRO score in patients treated with placebo. Patients treated with VYVGART experienced a marked reduction of key ocular symptoms: diplopia (double vision) and ptosis (drooping of the upper eyelids).
“Ocular myasthenia gravis significantly impacts patients’ daily lives, affecting vision, independence and the ability to do routine tasks, such as work or drive a car. Yet today, there are no approved targeted medicines for this disease,” said Carolina Barnett-Tapia, M.D., Ph.D., Associate Professor of Medicine (Neurology) at the University of Toronto. “The improvements observed with VYVGART in the OCULUS trial offer hope to the thousands of myasthenia gravis patients with ocular involvement.”
VYVGART was well tolerated and had a favorable safety profile in patients with oMG, consistent with prior studies. No new safety concerns were identified.
“ADAPT OCULUS is the first registrational study specifically designed to evaluate a targeted therapy for ocular myasthenia gravis,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. “Ocular MG has been historically under-studied and represents a significant unmet need in the MG community. These positive results deliver on our patient-centered approach to drug development and bring us one step closer to our vision of delivering a targeted, transformative treatment option to as many MG patients as possible and ensuring no patient is left behind.”
Data from the ADAPT OCULUS study will be presented at an upcoming medical meeting.
About the ADAPT OCULUS Study Design
ADAPT OCULUS is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group design study evaluating the efficacy and safety of VYVGART SC administered by prefilled syringe in adult patients with ocular MG (MGFA Class I) (n=141) across North America, Europe and Asia-Pacific. In Part A, randomized participants (1:1) received four once-weekly injections of efgartigimod PH20 SC or placebo PH20 SC followed by a 4-week follow-up. In Part B, open-label extension, participants received 2 cycles of four once-weekly efgartigimod injections with a 4-week interval between cycles. Additional cycles from Cycle 3 onward could start ≥1 week after the last administration of the previous cycle, based on clinical status.
The primary endpoint was the change from baseline in Myasthenia Gravis Impairment Index (MGII) (patient-reported outcome [PRO] subcomponent) ocular score at week 4 (day 29) compared to placebo in Part A. Enrolled participants were either seropositive or seronegative for AChR-Ab, and MGFA Class I with only ocular muscle weakness as determined by an MGII (PRO) ocular score of ≥6 with at least 2 ocular items with a score of ≥2. Participants were on a stable dose of gMG treatment prior to randomization, including acetylcholinesterase inhibitors, corticosteroids or nonsteroidal immunosuppressive drugs.
MGII is a validated measure of disease severity based on the signs and symptoms of myasthenia gravis and includes an ocular-specific subdomain that evaluates the two key clinical symptoms of oMG: diplopia and ptosis.
Important Safety Information
What is VYVGART® (efgartigimod alfa-fcab)?
VYVGART is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).
IMPORTANT SAFETY INFORMATION
Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. VYVGART can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
VYVGART may cause serious side effects, including:
Infection. VYVGART may increase the risk of infection. The most common infections were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain. Allergic Reactions (hypersensitivity reactions). VYVGART can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with VYVGART. Infusion-Related Reactions. VYVGART can cause infusion-related reactions. The most frequent symptoms and signs reported with VYVGART were high blood pressure, chills, shivering, and chest, abdominal, and back pain. Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.
Before taking VYVGART, tell your doctor if you:
take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have received or are scheduled to receive a vaccine (immunization), or have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding. What are the common side effects of VYVGART?
The most common side effects of VYVGART are respiratory tract infection, headache, and urinary tract infection.
These are not all the possible side effects of VYVGART. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.
Please see the full Prescribing Information for VYVGART and talk to your doctor.
Important Safety Information
What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?
VYVGART HYTRULO is a prescription medicine used to treat adults with:
generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.chronic inflammatory demyelinating polyneuropathy (CIDP). It is not known if VYVGART HYTRULO is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:
have an infection or fever.have recently received or are scheduled to receive any vaccinations.have any history of allergic reactions.have kidney (renal) problems.are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby. Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
VYVGART HYTRULO can cause side effects which can be serious, including:
Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection: fever, chills, frequent and painful urination, cough, pain and blockage or nasal passages, wheezing, shortness, sore throat, excess phlegm, nasal discharge.Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction: rash, swelling of the face, lips, throat, or tongue, shortness of breath, hives, trouble breathing, low blood pressure, fainting.Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction: high blood pressure, chills, shivering, chest, stomach, or back pain. The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.
These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see the full Prescribing Information for VYVGART HYTRULO and talk to your doctor.
About VYVGART and VYVGART Hytrulo
VYVGART® (efgartigimod alfa fcab) is a first-in-class human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. VYVGART® Hytrulo is a subcutaneous combination of efgartigimod alfa (VYVGART) and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics. VYVGART is approved for generalized myasthenia gravis (gMG) and immune thrombocytopenia (Japan only). VYVGART Hytrulo is approved for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo may be marketed under different proprietary names in other regions.
About Ocular Myasthenia Gravis (oMG)
Ocular myasthenia gravis (oMG) is a rare and chronic autoimmune disease characterized by muscle weakness limited to the muscles controlling the eyes and eyelids. Symptoms commonly include ptosis (drooping eyelids), diplopia (double vision), and fluctuating visual disturbance that can impair daily activities. Approximately 80% of myasthenia gravis (MG) patients initially present with ocular symptoms, and up to 92% experience ocular involvement at some point during the course of disease. While many progress to generalized myasthenia gravis (gMG), in 15–25% of patients, weakness remains restricted to the ocular muscles. oMG is driven by pathogenic IgG autoantibodies that disrupt communication at the neuromuscular junction. Despite the functional and quality-of-life burden associated with persistent ocular symptoms, there are currently no approved targeted therapies specifically for oMG. Treatment approaches often rely on symptomatic therapies and generalized immunosuppression, underscoring the need for additional therapeutic options for this distinct MG population.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).
FORWARD LOOKING STATEMENTS
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “advance,” “commit,” “continue,” “develop,” “potential,” and “will” and include statements argenx makes concerning the potential of VYVGART for oMG patients; argenx’s vision of delivering a targeted, transformative treatment option to as many MG patients as possible; its expectation that it will submit a Supplemental Biologics License Application (sBLA) for VYVGART for oMG to the U.S. FDA by end of third quarter 2026; its commitment to improve the lives of people suffering from severe autoimmune diseases; its plan to present data from the ADAPT OCULUS study at an upcoming medical meeting; its aim to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines; its commercialization of the first approved neonatal Fc receptor (FcRn) blocker and evaluation of its broad potential in multiple serious autoimmune diseases; and its advancement of several earlier stage experimental medicines within its therapeutic franchises. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.
2026-02-26 06:1617d ago
2026-02-26 00:3117d ago
NVIDIA CEO says artificial intelligence boom is just getting started: 'AI is going to be everywhere'
NVIDIA CEO Jensen Huang said the artificial intelligence boom is only just beginning and nowhere near its peak, predicting that AI is "going to be everywhere" as the industry enters a decade of growth.
Huang made the comments during an interview airing Thursday on FOX Business' "The Claman Countdown" with host Liz Claman.
"AI is just going to be everywhere. So we have plenty of runway, lots and lots of growth ahead of us," he said.
"It will take time, but we have lots of time," he continued. "I think this is where, at the beginning of probably about a decade of buildout, people think that it looks like a lot of capacity being built. But in fact, it's a very small amount of the total capacity the world needs. The amount of computation we need is far greater than the amount of capacity we're putting online this year and next year."
ALTMAN CALLS MUSK'S SPACE DATA CENTER PLANS 'RIDICULOUS' FOR CURRENT AI COMPUTING NEEDS
NVIDIA CEO Jensen Huang said the artificial intelligence boom is only just beginning. (Patrick T. Fallon/AFP via Getty Images / Getty Images)
Huang also said that his company has guided to zero revenue from sales to China in the current quarter, but they are "hoping for more."
Asked why that remains the case even after the Trump administration opened channels for certain chip sales to China, Huang said NVIDIA is still waiting on customers to decide how much to purchase.
"We've approved for some narrow licenses for some customers, and now the customers have to decide for themselves how much they're allowed to buy," Huang said.
He also said the concern that China is going to use American technology to advance its AI industry is "poorly placed."
JON TAFFER SAYS AI 'DOESN'T GET SICK' AS RESTAURANTS STRUGGLE TO FIND WORKERS
"Obviously, they have their own technology," he added. "I think the concerns about China relying on American technology to advance their AI industry are just poorly placed. AI includes energy. It includes the chip industry that we're part of. It also includes, of course, models and applications. And it's a fiber layer cake, if you will. Every single layer has an industry and all of those industries should go compete around the world to go secure AI leadership for the United States."
He emphasized that he believes the decision to block the United States out of the China market "has surely proven to be the wrong decision."
The NVIDIA executive went on to explain how jobs could be impacted by AI, predicting that it's "sensible" to expect that "some jobs will be obsolete in the future, many new jobs will be created and most jobs will be changed."
Though Huang noted that AI is creating jobs all over the U.S. through factories, data centers, chip plants and computer plants that need to be built to advance the technology.
"The number of trade skill labor jobs that we're creating around the United States is really quite extraordinary," he said. "I'm delighted to see it, and that's a whole segment of our economy and a whole of our society that we really would love to have built back in the United Sates so that we could become a reindustrialized country again."
Jensen Huang explains how jobs will be impacted by AI Nvidia president and CEO Jensen Huang discusses how artificial intelligence will reshape the workforce, arguing that while some roles may become obsolete, many new jobs will be created as AI transforms existing industries.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Addressing potential unemployment as a result of AI, he said, "one of the things that's really helpful is to think about work, think about jobs, both as a task that's involved in the job as well as the purpose of the job."
Huang further spoke on the progression of AI, saying that while it is already "super intelligent" in "narrow spaces," it is going to "change every single month."
"This year is going to be a pretty big breakthrough for artificial general intelligence, and we're seeing that now," he said. "We've seen that floodgate for enterprise usage of AI really starting to grow. So this is a great time."
The full interview with Jensen Huang airs Thursday at 3 p.m. EST.
2026-02-26 06:1617d ago
2026-02-26 00:3217d ago
Hensoldt reports revenue miss but defense boom supports backlog
A logo of defense supplier Hensoldt AG is pictured during Hensoldt's initial public offering (IPO) at the Frankfurt Stock Exchange in Frankfurt, Germany, September 25, 2020. REUTERS/Ralph... Purchase Licensing Rights, opens new tab Read more
Feb 26 (Reuters) - German defence contractor Hensoldt (HAGG.DE), opens new tab on Thursday reported full-year revenue slightly below market expectations but a surge in high-value orders and strong backlog demonstrated its gains from Europe's rearmament push.
The sensors and electronic warfare specialist reported 2025 revenue of 2.46 billion euros ($2.90 billion), below the 2.50 billion euro company-compiled consensus. The shortfall occurred despite what executives described as structurally rising demand, supported by Germany's defense reset and steady procurement activity by its NATO allies.
Make sense of the latest ESG trends affecting companies and governments with the Reuters Sustainable Switch newsletter. Sign up here.
"The geopolitical situation is forcing Europe to sustainably strengthen its defence capabilities," CEO Oliver Doerre said in a statement. "Germany has taken on a key role here and has been a major driver of our order intake momentum in 2025."
Germany retains a 25.1% golden share in the company, reflecting its sensitivity as a national security asset, while Italy's Leonardo (LDOF.MI), opens new tab holds roughly 23%.
Profitability remained resilient. Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose to 452 million euros, reflecting a margin of 18.4%, in line with expectations and above the company's own forecast.
Order intake jumped 62% to 4.71 billion euros, lifting its order backlog to 8.83 billion euros.
Still, the numbers highlight Hensoldt's constraints. Supply chain tightness in electronic components and ongoing hiring bottlenecks continue to shape the pace at which it can convert its backlog into revenue.
For 2026, Hensoldt forecast revenue of about 2.75 billion euros and set an adjusted margin target of 18.5%-19.0%.
Management also reiterated expectations for a sustained book-to-bill ratio in the 1.5-2.0 range -- a signal that it sees no cooling in demand for its radar, electronic warfare and optoelectronics devices.
Hensoldt's sensors equip platforms from the Eurofighter Typhoon to the Puma infantry fighting vehicle.
($1 = 0.8492 euros)
Reporting by Maria Rugamer; Editing by Matt Scuffham
Our Standards: The Thomson Reuters Trust Principles., opens new tab
2026-02-26 06:1617d ago
2026-02-26 00:3717d ago
ZipRecruiter, Inc. (ZIP) Q4 2025 Earnings Call Transcript
The company is moving in the direction that the new CEO is pushing it.
Opendoor Technologies (OPEN 2.64%) has earned a spot as a stock to watch since changing CEOs in September and launching a growth plan.
In its first earnings report since implementing this new strategy, it demonstrated progress, and the stock jumped after earnings. However, it's still 86% off its all-time highs. Is this a spectacular buying opportunity?
Image source: Getty Images.
Getting back to growth The market had high hopes for Opendoor when it went public. As a real estate disruptor, it has an enormous opportunity to shake up a huge, largely traditional industry with its digital focus.
It would be convenient to blame an inhospitable operating environment for the company's fall, but new CEO Kaz Nejatian immediately set to work identifying how to run the business better. His four-pronged plan, announced in September, has these goals:
Reach break-even adjusted net income by the end of the year on a forward one-year basis. Increase transaction velocity to drive positive unit economics. Transition to more direct-to-consumer relationships. Expand product options. The turnaround plan shows early signs of progress. Opendoor says it's on track to achieve its goal of break-even adjusted net income by the end of the year, generating cash to cover operating expenses. However, that's a tall order, given the capital required to buy houses. Companies with this type of model typically raise debt to cover high-cost inventory. It can still become profitable, but it's not easy.
In terms of transaction velocity, which means speeding up the rate of transactions, management said that the October acquisitions cohort sold at more than twice the rate of the October 2024 cohort, with 50% already sold or under contract.
Opendoor increased acquisitions by 300% sequentially in the fourth quarter of 2025. In the last week of the quarter, it purchased 537 homes, up from 128 in the last week of the third quarter.
As for product expansion, it aims to offer more options for customers to move the needle. Its Cash Plus plan has become very popular, accounting for 35% of contracts in the last week of the quarter, up from 19% in the last week of the third quarter for a much smaller pool.
Today's Change
(
-2.64
%) $
-0.14
Current Price
$
4.97
Nejatian is rebuilding the company from the ground up, using artificial intelligence (AI) to run a smarter business, become more efficient, and give his team the tools and motivation to innovate and improve its systems.
Overall, the business is moving in the direction Nejatian is pushing it. Focusing on volume rather than spread, or the home's markup, is driving momentum, and giving customers greater flexibility is closing more deals. Using AI is helping it achieve profitability, but the positive results so far are very short-term and are mostly showing up in reference to the October cohort.
It's going to take more time The market responded well to the news, but the numbers were still depressing. Year over year, nearly every metric was worse, from revenue and gross margin to homes bought and sold. Adjusted net loss improved, however, from $77 million to $62 million.
I think the company is showing signs of life, and over a long time period, it could be an exciting growth story. If you have a high appetite for risk and can afford to lose what you invest, you might want to take a small chance on Opendoor stock. But most investors should continue to wait and watch until there's greater stability and more progress.
2026-02-26 06:1617d ago
2026-02-26 00:4217d ago
Faraday Future to Kick Off 2026 EAI Robotics Deliveries Beginning Feb. 27 by Delivering to an Airbnb Operator; Establishes First U.S. “EAI Robot & Vehicle + Vacation Rental” Deployment
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (Nasdaq: FFAI) (“Faraday Future,” “FF,” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced its kick-off plans for its first EAI Robotics deliveries, just weeks after the Company announced its entry into the growing robotics industry. Its first deliveries are scheduled for February 27 to Golden Hills Investment LLC, a Florida-based high-end vacation rental investor and operator.
2026-02-26 06:1617d ago
2026-02-26 00:4717d ago
Alkami Technology, Inc. (ALKT) Q4 2025 Earnings Call Transcript
Idorsia delivers on its upgraded 2025 guidance, with strong QUVIVIQ sales growth, disciplined investment, and a significantly improved bottom line.Focused investment in Idorsia’s pipeline of first-in-class medicines to drive future growth, with key readout for daridorexant in pediatric insomnia imminent and Lucerastat registration study advancing in Fabry’s disease. Allschwil, Switzerland – February 26, 2026
Idorsia Ltd (SIX: IDIA) announces strong financial and operational results for the full year 2025, setting a new base for further growth ahead and a catalyst rich 2026.
Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented: “2025 marked a year of disciplined execution and renewed momentum for Idorsia. We delivered on our upgraded guidance, more than doubled QUVIVIQ sales, and significantly strengthened our financial position – demonstrating that focused investment and commercial excellence can go hand in hand. At the same time, we continued the next phase of growth: positioning TRYVIO/JERAYGO as the first treatment to target a new pathway in hypertension in decades and progressing our pipeline, including the upcoming readout of the pediatric insomnia study and the registrational program for lucerastat in Fabry disease. With multiple catalysts ahead, we enter 2026 with clarity, confidence, and a clear path toward sustainable growth.”
QUVIVIQ® (daridorexant)
Global 2025 net sales grow to CHF 134 million, reflecting outstanding year-over-year momentum – with continued strong growth ahead.QUVIVIQ continues to reshape the insomnia treatment landscape, and we are investing to accelerate its trajectory toward blockbuster status. Growth will be driven by expanded global reach through partnerships targeting general practitioners, strategic commercial alliances, additional public reimbursement wins, potential U.S. descheduling, adoption of innovative digital and distribution models, and the initiation of a U.S. label-enhancing study focused on daytime functioning.New opportunity to transform the treatment paradigm in pediatric insomnia with results expected in Q2 2026 from the Phase 2 study for daridorexant – the only dual orexin receptor antagonist in development for this population with high unmet need. TRYVIO™ / JERAYGO™ (aprocitentan)
TRYVIO is available in the US and used in the top 25 hypertension centers.Robust on-market experience among leading experts indicates “PRECISION-like” double-digit blood pressure reductions and confirms the tolerability profile across diverse patient groups.Regulatory success in 2025 – JERAYGO is approved in EU, UK, Switzerland, and Canada.Partnering discussions to maximize the global value of TRYVIO/JERAYGO are progressing. Research & Development
Alignment with the FDA on the registrational program for lucerastat, positioning Idorsia to advance the first oral therapy intended for all patients with Fabry disease.Advancing Idorsia’s immunology portfolio of first-in-class compounds – starting with Idorsia’s CCR6 antagonist proof-of-concept in psoriasis (proof-of-mechanism for other CCR6- and Th17-associated autoimmune diseases).Clinical validation for Idorsia's revolutionary drug-like synthetic glycan vaccine technology. Financial highlights for full year 2025
QUVIVIQ sales: CHF 134 millionContract revenue (one-off): CHF 72 million contract revenueNon-GAAP operating expenses: CHF 328 millionNon-GAAP operating loss: CHF 100 million including one-off contract revenue of CHF 72 million (US GAAP operating loss: CHF 33 million including CHF 90 million one-off income from Viatris agreement)Strengthened balance sheet through successful debt restructuring and new financing. Financial Guidance for 2026
QUVIVIQ sales: CHF 200 millionNon-GAAP operating expenses: approx. CHF 330 millionNon-GAAP operating loss: CHF 120 million (US GAAP operating loss: approx. CHF 160 million)Positive commercial contribution and focused investment in value-driving pipeline assets results in continued improvement of underlying business performance. 2026 guidance reflects continued growth of QUVIVIQ (approximately 50% increase in Idorsia-led sales), investment in the lucerastat registration program, and development of the company’s immunology portfolio. TRYVIO/JERAYGO revenues and investments are not included, as these will be considered in any potential partnership agreement. All amounts exclude unforeseen events and any potential upsides from new direct-to-patient distribution models currently being implemented in several geographies and revenue related to additional business development activities.
Financial results
US GAAP resultsFull YearFourth Quarterin CHF millions, except EPS (CHF) and number of shares (millions)2025202420252024Net revenue2211134860Operating expenses(268)(351)(106)(140)Operating income (loss)(33)(232)(56)(78)Net income (loss)(112)(264)(78)(84)Basic & diluted EPS(0.52)(1.45)(0.31)(0.45)Basic & diluted weighted average number of shares214.7182.4248.3188.3 Net revenue of CHF 221 million in 2025 resulted from product sales (CHF 134 million), product sales to partners (CHF 7 million), and contract revenues (CHF 79 million). This compares to net revenue of CHF 113 million in 2024 as a result of QUVIVIQ product sales (CHF 61 million), product sales to partners (CHF 47 million), and contract revenue (CHF 5 million).
US GAAP operating expenses of CHF 268 million in 2025 and CHF 351 million in 2024 were impacted by a one-off gain of CHF 90 million (Viatris deal amendment) in 2025 and CHF 125 million (Viatris deal) in 2024, respectively. Excluding these one-off gains, US GAAP operating expenses for 2025 decreased by CHF 83 million, mainly driven by R&D expenses of CHF 102 million decreasing by CHF 42 million compared to 2024 (CHF 144 million), and SG&A expenses of CHF 221 million decreasing by CHF 52 million compared to 2024 (CHF 273 million).
US GAAP net loss in 2025 amounted to CHF 112 million compared to CHF 264 million (net loss) in 2024. The reduced net loss in 2025 was primarily driven by revenue growth and lower operating expenses as a result of an operational restructuring initiated in Q4 2024.
The US GAAP net loss resulted in a net loss per share of CHF 0.52 (basic and diluted) in 2025, compared to a net loss per share of CHF 1.45 (basic and diluted) in 2024.
Non-GAAP* measuresFull YearFourth Quarterin CHF millions, except EPS (CHF) and number of shares (millions)2025202420252024Net revenue2141134760Operating expenses(328)(427)(96)(121)Operating income (loss)(100)(308)(47)(60)Net income (loss)(118)(330)(54)(73)Basic and diluted EPS(0.55)(1.81)(0.22)(0.39)Basic and diluted weighted average number of shares214.7182.4248.3188.3 * Idorsia measures, reports, and issues guidance on non-GAAP operating performance. Idorsia believes that these non-GAAP financial measurements more accurately reflect the underlying business performance and therefore provide useful supplementary information to investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.
Non-GAAP net loss in 2025 amounted to CHF 118 million; the difference versus US GAAP net income was mainly driven by the one-off gain from the amendment of the Viatris deal (CHF 90 million), depreciation and amortization (CHF 17 million) , share-based compensation (CHF 6 m), impairment charges (CHF 3 m), restructuring charges (CHF 3 m), accretion and issuance cost amortization (CHF 16 m) and a debt extinguishment loss related to the debt restructuring (CHF 37 million).
The non-GAAP net loss resulted in a net loss per share of CHF 0.55 (basic and diluted) in 2025, compared to a net loss per share of CHF 1.81 (basic and diluted) in 2024.
Liquidity and indebtedness
Liquidity on December 31, 2025, amounted to CHF 89 million. This amount does not include the remaining CHF 80 million available under the new money facility (term loan).
(in CHF millions)Dec 31, 2025Sep 30, 2025Dec 31, 2024Liquidity Cash and cash equivalents8964106Total liquidity*8964106 Indebtedness Convertible loan335335335Convertible bonds4949797Debt notes**753753-Term loan1813-Other financial debt187186189Total indebtedness1,3421,3361,321 *rounding differences may occur
** The debt notes issued by Idorsia Investments SARL in exchange for convertible bonds are senior secured with the shares in Idorsia Investments SARL. The A Notes only benefit from a limited and subordinated Swiss-law governed guarantee by Idorsia Ltd.
Human Resources
Idorsia reduced more than 200 positions worldwide in 2025, bringing the total number of permanent employees to 487 (2024: 689).
Annual Report
Idorsia's Annual Report 2025 – consisting of the Business Report, Governance Report, Compensation Report, Sustainability Report, and Financial Report, is available at www.idorsia.com/annual-report.
Note to Shareholders
The Annual General Meeting (AGM) of Shareholders to approve the Annual Report of the year ending December 31, 2025, will be held on Wednesday, May 6, 2026.
Registered shareholders with voting rights individually or jointly representing at least 0.5% of the share capital of the company, being entitled to add items to the agenda of the general meeting of shareholders, are invited to send in proposals, if any, to Idorsia Ltd, attention Corporate Secretary, Hegenheimermattweg 91, CH-4123 Allschwil, to arrive no later than March 22, 2026. Any proposal received after the deadline will be disregarded.
In order to vote at the Annual General Meeting, shareholders must be registered in the company's shareholder register by April 27, 2026, 17:00 CEST, at the latest.
Results Day Center
Investor community: To make your job easier, we provide all relevant documentation via the Results Day Center on our corporate website: www.idorsia.com/results-day-center.
Events
First Quarter 2026 Financial Results reporting on April 28, 2026Annual General Meeting of Shareholders on May 6, 2026Half-Year 2026 Financial Results reporting on July 30, 2026 Notes to the editor
About Idorsia
The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).
For further information, please contact
George Thampy
Senior Vice President, Head of Investor Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10 [email protected] – [email protected] – www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
This release contains forward-looking statements based on current assumptions and forecasts made by the Group. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the Group and the estimates given here.
(Figures in brackets refer to the corresponding period last year1)
26 February 2026 – Prosafe SE reported EBITDA of USD 21.1 million (USD 8.4 million) for the fourth quarter of 2025. All the company’s five vessels generated revenue through-out the quarter, with four units active during the full period and the Safe Boreas arriving in Australia ahead of the expected start of operations in the first quarter of 2026.
Full-year 2025 EBITDA was USD 40.0 million, at the high end of the guided range for the year, and up from USD 27.2 million in 2024. Based on the increased order backlog, continued market improvements, reduced costs and the 2025 recapitalisation, Prosafe is set to deliver continued earnings growth in 2026 with full-year EBITDA expected in the range of USD 45-55 million.
Operations and HSSE
100% fleet utilisation in Q4 2025 with all 5 units on contractGood operating and safety performanceSafe Boreas on full day rate from 15 December 2025All Safe Caledonia options exercised with operations completed 22 FebruarySafe Caledonia awarded letter of intent (LOI) for 6 months plus options in 2027/28Backlog of USD 428 million incl. options and excluding Safe Caledonia LOISPSs for Safe Zephyrus and Safe Notos moved to March/April 2026 Financials
Revenues of USD 70.9 million (USD 37.0 million)EBITDA of USD 21.1 million (USD 8.4 million)Cash flow from operations of USD (3.0) million (USD 0.1 million)Capex of USD 8.5 million (USD 8.0 million)Liquidity position of USD 65.3 million (USD 46.8 million)NIBD of USD 230.8 million (USD 369.1 million) Market and outlook
All high-end units contracted through 2026 and into 2027Strong global market led by increased demand in Brazil and AfricaFocused on contract renewals for Safe Eurus and Safe ZephyrusSafe Caledonia marketed for additional opportunities prior to the 2027 LOIExploring strategic opportunities/M&A Please see the fourth quarter 2025 presentation for further details.
Reese McNeel, CEO of Prosafe, says, “Prosafe moves into 2026 with a strong foundation for long-term value creation with all high-end vessels on contract into 2027 and a backlog at a near ten-year high reflecting significant commercial progress through new contracts at materially higher dayrates. We are on track to deliver strong EBITDA growth supported by cost- efficient operations and capital discipline in a tightening global offshore accommodation market.”
1) Comparable figures for fourth quarter and full year 2024 are based on the audited results presented in the 2024 Annual Report with adjustments related to the subsequent Safe Concordia sale and impairment in March 2025.
Presentation
Reese McNeel, CEO, and Halvdan Kielland, CFO, will today present the results at Pareto Securities, located at Dronning Mauds gate 3, 0115 Oslo, at 12:00 CET. This presentation is open to the public and will be live-streamed on Prosafe's website.at www.prosafe.com (http://www.prosafe.com).
It will be possible to ask questions by using the Q&A tool embedded in the webcast. A replay of the webcast will be made available on Prosafe's website shortly after the presentation.
The Q4 2025 press release and presentation are attached and available at https://www.prosafe.com and www.newsweb.no (https://www.newsweb.no).
Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Euronext Oslo Børs with ticker code PRS. For more information, please refer to www.prosafe.com (http://www.prosafe.com).
For further information, please contact:
Reese McNeel, CEO
Phone: +47 415 08 186
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
February 26, 2026 01:00 ET | Source: Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences.
Molecular Partners will also issue its full-year 2025 financial report, along with its Annual Report, on March 12, 2026.
Details of the events:
TD Cowen 46th Annual Health Care Conference
Boston, MA, March 2-4, 2026
Molecular Partners CEO Patrick Amstutz will take part in a fireside chat on Monday, March 2 at 2.30-3.00 pm ET (8.30-9.00 pm CET).
Leerink Partners Global Healthcare Conference 2026
Miami, FL, March 9-11 March, 2026
Molecular Partners CEO Patrick Amstutz will take part in a fireside chat on Monday, March 9 at 4.20-4.50 pm EDT (9.20-9.50 pm CET).
Full Year 2025 Financial Results Announcement
Thursday, March 12, 2026 at 4.00 pm EDT (9.00 pm CET).
Both fireside chats will be made available on the Company’s website under the investor section.
About Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs
For further details, please contact:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S. [email protected]
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland [email protected]
Tel: +41 44 575 19 35
This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, "anticipate", “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth in under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com.
Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
2026-02-26 06:1617d ago
2026-02-26 01:0017d ago
dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program
dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program
Kaiseraugst (Switzerland), Maastricht (Netherlands), February 26 2026
dsm-firmenich, innovators in nutrition, health, and beauty, announces that following the completion of its €1.08 billion share buyback program in 2025, the company has cancelled 12,049,441 shares. As a result, the total number of issued shares has been reduced by approximately 4.5%, from 265,676,388 to 253,626,947 shares.
About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm-firmenich is a Swiss company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com
Disclaimer
This press release does not constitute or form part of, an offer or any solicitation of an offer for securities in any jurisdiction. This communication is not for release, distribution or publication, whether directly or indirectly and whether in whole or in part, into or in the United States of America or any (other) jurisdiction where any of such activities would constitute a violation of the relevant laws of such jurisdiction.
The offer of bonds referred to in this communication was limited in the EEA and the United Kingdom to qualified investors only. The bonds have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and will also not be registered with any authority competent with respect to securities in any state or other jurisdiction of the United States of America. The bonds may not be offered or sold in the United States of America without either registration of the securities or an exemption from registration under the US Securities Act being applicable.
The English language version of this press release prevails over other language versions.
Press release_dsm-firmenich cancels shares following completion of share repurchase program_20260226
In 2025, Wendel accelerated the transformation of its business model:
€1591 million of proforma FRE generated by Wendel Investment ManagersStrengthened operational profile of Wendel Principal Investments
Strong progress in the execution of the 2030 strategic roadmap announced in December 2025:
€1.65 billion of disposals announced to date More than €5002 million to be returned to shareholders in 2026
Fully diluted3 NAV per share of €164.2 as of December 31, 2025
Wendel Investment Managers: strong organic growth in revenues and fundraising in 2025, continued build-out of the platform
Wendel Investment Managers, Wendel's third-party asset management platform reached €41.2 billion assets under management as of December 31,2025 and will reach €47 billion AuM upon completion of the acquisition of Committed Advisors4.The acquisition of Committed Advisors illustrates the attractiveness of the platform, adding new expertise: the secondary market.Over the year, WIM’s GPs5 have raised €4.5bn of equity Nearly €8 billion deployed in Europe and the United States in the mid-market segment207% FPAuM growth in 2025 including 13% organic growth.Management fees & others totaled €349 million reported in 2025, growing by +177% compared to 2024, thanks to strong organic growth and including 9 months of Monroe Capital activity. Management fees & others totaled €404 million on 12 months proforma basis.Reported Fee Related Earnings (FRE) totaled €139.5 million in 2025 and €159 million proforma 12 months, in line with the target announced in October 2024 of €160 million. Wendel Principal Investments: robust overall activity performance and strong portfolio rotation over 2025
Good consolidated revenue growth: +6.1% vs. 2024Good operating performance of Bureau Veritas and Globeducate, and a sharp rebound at ACAMSNew leadership at CPI and ScalianPortfolio rotation: In 2025: €1.3 billion proceeds from the disposal of shares of Bureau Veritas through two transactions completed in March and SeptemberIn 2026: €1.65 billion proceeds expected from the disposals of Stahl and IHS6 announced in February Operational transformation: Wendel has created a unique private asset investment ecosystem in North America and Europe, powered by two complementary value creation engines. This ecosystem is supported by an optimized operating model and a robust financial structure.
Wendel Investment Managers (WIM): Following the acquisition of Committed Advisors, WIM is expected to generate FREF7 in excess of €20018 million in 2026 (on a pro forma basis) across private equity, private debt and private market solutions, supported by teams with a strong track record of performance and a highly diversified institutional investor base (LPs)WIM benefits from strong recurring revenues and boasts significant growth potential, with an average organic2F9 FRE annual growth target of 15% through to 2030Wendel will continue to assess selective external growth opportunities to potentially strengthen its platform and expertise Wendel Principal Investments (WPI): WPI has awarded IK Partners an advisory mandate to strengthen the value creation of its private controlled assets and benefit from the proven expertise of its ecosystem for new and existing investments;Dynamic management of the listed and unlisted portfolio to continue until the end of 2030; Objective to achieve an average annual increase in the intrinsic value of Wendel’s Principal Investments of 12% to 16% Fully diluted Net Asset Value as of December 31, 2025: €164.2 per share, slight increase vs Q3 of +0.7% and +1.7% restated from the interim dividend paid in November 2025
Fully diluted NAV per share slightly improving by €1.2 per share in Q4, mainly reflecting the impact of the increase in the value of Stahl based on the signed purchase offer which is c.20% above the value recorded in the September 30, 2025 NAV. For the remainder, value creation by activity can be analyzed as follows: Wendel Investment Managers (c.26% of GAV excluding cash): total value in NAV down by €1.3 per share compared to the end of September impacted by the decrease in listed comparable GPs' valuation multiples. Asset management now represents c.26% of GAV excluding cash10.Listed assets (c.29% of GAV excluding cash): total value up by €1.2 per share due to Bureau Veritas’ and IHS' share prices slight increase over Q4. Of note, Tarkett that is no longer listed and is now included in the non-listed assets value.Unlisted assets (c.44% of GAV excluding cash): total value up by €3.7 per share over Q4, mainly due to Stahl’s transaction price which is expected to be completed at a premium of c.20% compared to the last value booked in NAV on September 30, 2025.The remaining change in NAV per share in the fourth quarter mainly reflects the payment of the €1.5 interim dividend in November 2025. Increasing shareholder returns, in line with the strategic roadmap
Ordinary dividend of €5.1 per share for 2025 will be submitted for approval at the next Shareholders’ Meeting, to be held on May 2026. It will be up by +8.5% compared to 2024, equivalent to 3.1%11 of December 31, 2025 NAV and representing a 5.8%12 yield on Wendel’s share price as of February 25, 2026An interim dividend of €1.50 has been paid on November 20, 2025. The balance of the dividend for 2025 will be submitted for approval at the next Shareholders’ Meeting, to be held on May 21, 2026The next interim dividend is expected to represent 50% of the dividend paid for 2025.Expected launch of a share buyback program covering 9% of the capital as of February 27, 2026, representing an amount of approximately €340 million, on the current share price basis. Strong financial structure and committed to remain Investment Grade
Debt maturity of 4.0 years with an average cost of 2.6%LTV ratio at 9.6%13 as of December 31, 2025 on a pro forma basis taking into account future investment commitments in IK Partners and Monroe Capital funds, the acquisition of Committed Advisors, the disposals of Stahl and IHS and the share buyback.Cash position: €2.2 billion + €875 million in committed credit facility (fully undrawn) Net income: €344.7 million
Consolidated net sales up 6.1% to 7,567.9 M€Stable net income from operations at €753.0 million from €753.7 million in 2024Consolidated net income totaled €344.7 million, down compared to 2024 due to non-recurring items in 2024, notably the €692 million capital gain on the sale of Constantia Flexibles. Net loss, group share, at €-151.8 million in 2025, compared to an income of €293.9 million in 2024, mainly due to the evolution of non-recurring items compared to 2025. Gain on transaction on Bureau Veritas shares in 2025 and IHS Towers share price increase are not accounted in P&L but in shareholder equity, for a positive impact of €1.2 billion. Laurent Mignon, Wendel Group CEO, commented:”The year 2025 was marked by an acceleration in the shift of Wendel’s growth profile, Over the past three years, Wendel has become a global investment firm with a unique model dedicated to private assets, offering two complementary businesses that create long-term value: our long-standing WPI business, dedicated to direct principal investments, and third-party asset management with WIM.
These two powerful engines of growth and value creation, and an organization that is now streamlined and focused on expertise and operational efficiency, enable Wendel to launch in December 2025 a new phase in its development for the benefit of its shareholders and clients.
The recurring cash flows generated by asset management and proceeds from portfolio disposals are expected to generate a solid cash inflow of more than €7 billion by 2030 and will enable the return of more than €1.6 billion to shareholders in dividends and share buybacks. In two months, we have already demonstrated our ability to deliver on these strategic ambitions, with €1.65 billion of disposals announced to date, highlighting the quality of these assets, and over €500 million of shareholder returns in 2026 through share buybacks and dividend.
In 2026, we will continue the rollout of WIM, which now operates in three asset classes: private equity, private debt, and private market solutions, and which is expected to exceed €200 million of pro forma FRE. WIM will represent already 38% of Wendel assets, pro forma of Committed Advisors’ acquisition and Stahl and IHS disposals. Finally, we will continue to strengthen WPI, notably supported by the advisory mandate entrusted to IK Partners will pursue its development and its value creation journey.”
Wendel’s net asset value as of December 31, 2025: €164.2 per share on a fully diluted basis
Change in NAV compared to Q3 2025:
Wendel’s Net Asset Value (NAV) as of December 31, 2025, was prepared by Wendel to the best of its knowledge and on the basis of market data available at this date and in compliance with its methodology.
Fully diluted Net Asset Value was €164.2 per share as of December 31, 2025 (see detail in the table below), as compared to €163.0 on September 30, 2025, representing an increase of €1.2 per share since September. Compared to the last 20-day average share price as of December 31, the discount to the December 31, 2025, fully diluted NAV per share was -51.3%.
The change in NAV in the fourth quarter breaks down as follows:
WIM’s contribution to NAV growth was slightly negative, -€1.3 per share in Q4 due to the decrease in listed comparables’ multiples used for the valuation of IK Partners’ and Monroe Capital. A total of €217 million of sponsor money is included in the NAV as of end of December, corresponding to investments in funds managed by IK Partners and Monroe Capital.WPI contributed positively to value creation in the fourth quarter with a gain of €4.9 per share: Concerning listed assets, Bureau Veritas contributed positively to Net Asset Value, as end of December 2025, its 20-day average share price was up QTD (+1.9%) same as, IHS Towers (+4.8% 20-day average share prices). Total value creation per share of listed assets was up (+€1.2) on a fully diluted basis over the fourth quarter. Note that Tarkett is no longer listed and is now included in the unlisted assets value.Unlisted assets contribution to NAV was positive over the fourth quarter with a total change of +€3.7 per share, mainly reflecting Stahl’s valuation at the disposal price, exhibiting a premium of over 20% compared to the value retained in September.Cash operating costs, net financing results and other items impacted NAV by -€0.8 per share over Q4, reflecting contained operating costs, offset by positive financial income. Total Net Asset Value increase amounted to +€1.2 per share since September 30, 2025 and by €2.7 restated for the interim dividend paid in November 2025
Over 2025, Fully diluted Net Asset Value, is decreasing by -4.5 % restated for the dividend paid in 2025 and the FX impact and by -11.6% in total. Compared to the last 20-day average share price as of December 31, 2025 the discount to the December 31, 2025, fully diluted NAV per share was -51.3%.
Fully diluted NAV per share of €164.2 as of December 31, 2025
(in millions of euros) Dec. 31,
2025Sept. 30, 2025Dec. 31, 2024 Listed investmentsNumber of shares Share price (1)2,1702,2713,793 Bureau Veritas66.6m/66.6/120.3m€26.6/€26.1/€29.51,7751,7423,544 IHS63.0m/63.0m/63.0m$7.4/$7.0/$3.2395377192 Tarkett unlisted/€17.0/€10.5-15257 Unlisted assets (2)3,2972,9653,612 Wendel Investments Managers (3) 1,9441,888616 Asset Managers (IK Partners & Monroe)1,7271,821616 Sponsor Money21767- Other assets and liabilities of Wendel and holding companies (4)16127174 Net cash position & financial assets (5)2,2002,4482,407 Gross asset value 9,6279,69910,603 Wendel bond debt -2,397-2,381-2,401 IK Partners transaction deferred payment and Monroe earnout-235-235-131 Net Asset Value 6,9957,0828,071 Of which net debt -432-169-124 Number of shares 42,823,53744,512,03844,461,997 Net Asset Value per share€163,3€159.1€181.5 Wendel’s 20 days share price average €79.9€80.6€93.5 Premium (discount) on NAV(51.1)%(49.3)%(48.5)% Number of shares – fully diluted 42,391,15042,413,58542,466,569 Fully diluted Net Asset Value, per share €164.2€163.0€185.7 Premium (discount) on fully diluted NAV (51.3)%(50.6)%(49.6)% (1) Last 20 trading days average as of December 31,2025, September 30, 2025, December 31, 2024. Tarkett share price as of September 30, 2025 is based on ongoing Tender Offer.
(2) Investments in unlisted companies (Tarkett, Stahl, Crisis Prevention Institute, ACAMS, Scalian, Globeducate, Muno, Wendel Growth). Aggregates retained for the calculation exclude the impact of IFRS16. Globeducate valued based on transaction multiples. Stahl valued based on transaction price. Tarkett valued based on squeeze-out price.
(3) Investments in IK Partners and Monroe (excl. Cash to be distributed to shareholders). Valued as a platform based on Net Income / Distributable earnings multiples.
(4) Of which 432,387 treasury shares as of December 31,2025, 2,098,453 as of September 30, 2025 and 1,995,428 as of December 31, 2024.
(5) Cash position and financial assets of Wendel & holdings.
Assets and liabilities denominated in currencies other than the euro have been converted at exchange rates prevailing on the date of the NAV calculation.
If co-investment and managements LTIP conditions are realized, subsequent dilutive effects on Wendel’s economic ownership are accounted for in NAV calculations. See page 285 of the 2024 Registration Document.
Wendel’s Principal Investments’ portfolio rotation
In 2025 Wendel realized a total of €1.3 billion in disposals for its own account:
On March 12, 2025, Wendel implemented a prepaid 3-year forward sale representing approximately 6.7% of Bureau Veritas share capital. The transaction immediately generated net cash proceeds of approximately €750M to Wendel.On September 16, 2025, Wendel successfully disposed of 23.3 million Bureau Veritas shares underlying the exchangeable bond into Bureau Veritas shares issued by Wendel in March 2023 and maturing in March 2026, for a total amount of approximately €591M. Wendel reinvested c.€100M in Scalian in 2025 to support its external growth and to strengthen its balance sheet. Early 2026, Wendel announced the following transactions:
Sale of Stahl: a significant step forward in our €7bn capital allocation strategy announced in December 2025. Wendel has entered into an agreement to sell its stake in Stahl (excluding Muno) for an enterprise value of €2.1 billion to Henkel, a German-headquartered global coatings and adhesives leader serving a broad range of industrial and consumer end markets. The contemplated transaction values Stahl at a level that would yield total net proceeds at completion (after debt and transaction costs) of c.€1.2 billion for Wendel. This corresponds to a multiple of 6.6 times Wendel’s total investment since 2006, including €427m of past proceeds thanks to Stahl’s robust cash generation. This represents an annualized IRR of over 15% over 20 years. This compares with a value of €960 million in Wendel’s net asset value (“NAV”) published before the transaction announcement, as of September 30, 2025. This transaction is a great illustration of the quality of Wendel Principal Investments (WPI) assets and the cautiousness of their value in our Net Asset Value with a value to be realized representing a premium of over 20%. Wendel supports MTN’s offer to acquire IHS Towers pursuant to which it will receive full liquidity on its 19% stake, representing net proceeds of approximately $535m. Upon closing, Wendel will receive full liquidity on its c.19% stake in IHS, representing proceeds of approximately $535m to Wendel. The selling price represents a 21% premium over Wendel’s latest reported Net Asset Value (September 30, 2025). Together, these two transactions will generate approximately €1.65 billion and give Wendel full flexibility to achieve its long-term value creation objectives through investments in private assets, the development of Wendel Investment Managers (WIM), and a higher return to shareholders
Wendel Investment Managers
c.26% of Gross Asset Value excluding cash (c.30% proforma of Committed Advisors)
Over 2025, the Wendel Asset Management platform (IK Partners and Monroe Capital), focused on the midmarket private markets, registered particularly strong levels of activity, generating a total of €349 million in Management fees and others, up 177 % vs. 2024, thanks to good organic growth and strong scope effects: IK Partners was consolidated from the end of April 2024, whereas in 2025, IK Partners was consolidated for the full year, and Monroe Capital has been consolidated since the end of March 2025.
As a consequence, the consolidated Fee Related Earnings of the platform amounted to €139.5 million in 2025, up 146% vs last year, and Recurring Profit Before Tax (FRE+PRE) was €145.6 million, up 156% vs. last year.
On a full year proforma basis, WIM FRE would have amounted to €159 million at constant exchange rates, in line with the target announced in October 2024 of €160 million.
The Wendel Asset Management Platform has known a Strong Momentum in terms of fund raising with €4.5 billion raised over the year including €1.3 billion for IK Partners and $3.8 billion for Monroe Capital.
Since joining Wendel Investment Managers, IK Partners, a leading European private equity firm (announced in October 2023), and Monroe Capital, a US private debt specialist (announced in October 2024), have together raised more than €11 billion through their closed-end funds14. This remarkable performance demonstrates the strong appeal of the Wendel Investment Managers platform.
As of December 31, 2025 Wendel’s third-party asset management platform15 represented total assets under management of €41.2 billion (of which €10.6 billion of Dry Powder16), and FPAuM17 of €31.0 billion, FX adjusted, up +207% year-to-date. Over the period, €9.2 billion of new Fee Paying AuM were generated and about €5.2 billion of exits and payoffs have been realized.
The platform's model and dynamics attract new talent.
The signing of a new acquisition with Committed Advisors in October 2025 will enable us to reach $47 billion in AuM and integrate new expertise with strong organic growth potential: the secondary market. This transaction is expected to be finalized in the first quarter of 2026A 16% increase in headcount by 2025 to strengthen the platform's organic growth capacity. Sponsor money invested by Wendel
Wendel uncalled commitments in IK Partners, Monroe Capital and Committed Advisors funds amount to €575 million. As of December 31, 2025, a value in the NAV of €217 million of sponsor money has been called in IK Partners and Monroe Capital funds.
Principal Investment companies’ value creation and performance
Figures post IFRS 16 unless otherwise specified.
Listed Assets: 29% of Gross Asset Value excluding cash
Bureau Veritas: Sector leading organic revenue growth of 6.5% in FY 2025. Strong margin improvement to 16.3% in FY 2025. Positive growth outlook with continued margin expansion in 2026. New €200 million share buyback.
(full consolidation)
In the full year of 2025, Bureau Veritas reported total revenue of €6,466.4 million, marking a 3.6% increase compared to 2024. Organic revenue growth was 6.5% compared to full year 2024, with a 6.3% increase in the fourth quarter of 2025. This growth was driven by solid underlying trends across most businesses and geographies.
Full year adjusted operating profit increased by 5.7% to €1,052.9 million and increased by 51 basis points at constant currency. This represents an adjusted operating margin of 16.3%, up 32 basis points compared to the full year 2024. Adjusted attributable net profit totaled €631.4 million in 2025, up 1.7% vs. €620.7 million in 2024. Adjusted EPS stood at €1.42 in 2025, and a 2.8% increase versus 2024 (€1.38 per share) and of a 9.2% increase based on constant currencies.
2026 outlook
Bureau Veritas is starting the third year of LEAP I 28 strategy with sound market fundamentals. Building on a strong 2025 performance, Bureau Veritas aims to deliver full year results for 2026 that align with the financial ambition outlined in its strategy:
Mid-to-high single-digit organic revenue growth, Improvement in adjusted operating margin at constant exchange rates, Strong cash flow generation.
Return to shareholders: Proposed dividend of €0.92 and new €200 million share buyback to be launched in 2026
The Board of Directors of Bureau Veritas is recommending a dividend of €0.92 per share for 2025, up 2.2% compared to the prior year. This corresponds to a payout ratio of 65% of its adjusted net profit. This is subject to the approval of the Shareholders’ Meeting to be held on May 19, 2026.In line with the commitment to continue to improve shareholder returns, on February 25, 2026, a new €200 million share buyback program is announced, to be completed within the next twelve months. The program is subject to approval by the Annual General Meeting of May 19, 2026 if any or all is to be executed after that date.In 2025, double-digit shareholder returns were achieved based on EPS growth of c. 9%. For further details: group.bureauveritas.com
IHS Towers – IHS Towers will report its FY 2025 results in March 2026
Unlisted Assets: 44% of Gross Asset Value excluding cash
(in millions)SalesEBITDANet debt 202420252024 including IFRS 162025 including IFRS 16Δ2025 End of December including IFRS 16CPI(1)$150.1$152.9$74.0$75.7+2.3%$428.2ACAMS$102.1$111.5$25.1$27.2+8.4%$164.0Scalian €533.4€505.9€59.8€54.9-8.2%€366.9Globeducate(2) €376.2€415.9n.a€108.2+28.5%€826.2 (1) In accordance with IFRS 5, the contribution of CPI France has been reclassified in "Net income from discontinued operations and operations held for sale” in 2025 with an impact of €0.4M. Comparable sales for 12M 2024 represent €138.3M versus 2024 published sales of €138.8M. The difference of €0.5M corresponds to CPI France classified as assets held for sale and discontinued operations in accordance with IFRS 5. EBITDA FY 2025 is excluding French activities. which has been treated as a discontinued operation.
(2) Globeducate acquisition was completed on October 16th, 2024. For FY 2025 and FY2024, contribution of 12 months of sales from December 1st, to November 30st including India.
Stahl – Agreement to sell Stahl, the global leader in specialty coatings for flexible materials, to Henkel. Estimated net proceeds of €1.2 billion for Wendel, representing an annualized IRR of over 15% since 2006
(full consolidation)
On February 4th, 2026, Wendel announced it has entered into an agreement to sell its stake in Stahl (excluding Muno) for an enterprise value of €2.1 billion to Henkel, a German-headquartered global coatings and adhesives leader serving a broad range of industrial and consumer end markets.
The contemplated transaction values Stahl at a level that will yield total net proceeds at completion (after debt and transaction costs) of c.€1.2 billion for Wendel. This corresponds to a multiple of 6.6 times (net) Wendel’s total investment since 2006, including €427m of past proceeds related to Stahl’s robust cash generation. This represents an annualized IRR of over 15% over 20 years. Expected proceeds compare with a value of €960 million in Wendel’s last net asset value (“NAV”) published before the transaction announcement, as of September 30, 2025.
The transaction is subject to mandatory consultation processes and the satisfaction of customary closing conditions, including regulatory approvals.
Crisis Prevention Institute reports +1.8% revenue and EBITDA is slightly increasing +2.3% year on year
(full consolidation)
CPI reported 2025 revenue of $152.9 million, an increase of +1.8% year over year, or +0.9% organically on a foreign-exchange-neutral basis. North American performance remained broadly stable (–0.7% vs. 2024) despite continued federal oversight and funding uncertainty across CPI’s end markets.
International operations delivered strong momentum, with revenue outside North America growing +24% year over year. These results exclude France, where CPI made the strategic decision to discontinue operations in Q4 2025 following several years of underperformance.
Full Year 2025 EBITDA was $75.7 million18, up 2.3% from 2024, reflecting modest margin improvement to 49.5% (from 49.3% in 2024).
As of December 31, 2025, net debt totaled $428.2 million19, or 5.2x EBITDA as defined in CPI’s credit agreement. In Q3 2025, CPI raised $60m in incremental debt to fund a shareholder dividend ($34 million to Wendel) and repurchase management’s stock and options, net of reinvestment.
ACAMS – Total sales up + 9.2% and solid margin at 24.4% reflecting strategic investments of recent years
(full consolidation)
ACAMS, the global leader in training and certifications for anti-money laundering and financial crime prevention professionals, generated 2025 revenue of $111.5 million, up 9.2% vs. 2024. Results for the FY 2025 were driven by recovery in conference sponsorship & exhibition (“S&E”) up by 45% vs 2024 and the APAC region (+9% vs LY), continued growth across the Americas +13%, offset by weaker performance in Europe which continues to be affected by softness in the European banking market.
Strategic investments made by ACAMS in the past few years have positively impacted performance, including the appointment of new Executive Leadership Team members, enhancements made to the Company’s technology platform, and market expansion with the introduction of the Certified Anti-Fraud Specialist certification (CAFS). In January 2026, ACAMS released a new digital member experience powered by a technology-enabled content platform, laying the foundation for ACAMS’ next phase of growth.
EBITDA20 in 2025 was $27.2 million, up 8,3% vs. 2024, and reflecting a margin21 of 24.4%, slightly down 20 bps year-over -year.
As of December 31, 2025, net debt totaled $164.0 million22, slightly down from $165.0 million at the end of 2024, which represents 5.0x EBITDA leverage as defined in ACAMS’ credit agreement, with ample room relative to the 9.5x covenant level.
Scalian - Decrease of total sales of -5.1 % in 2025, in the context of continued market growth slowdown. EBITDA margin at 10.9%, down c. 30 bps, in persisting challenging market conditions
(Full consolidation)
Scalian, a European leader in digital transformation, project management and operational performance consulting, reported total sales of €506 million as of December 31, 2025, a -5.1% decrease vs. 2024. The slowdown is spread across several sectors and geographies, primarily in France reflecting reflecting a sharp slowdown in IT activities (mainly small clients) and continued weakness in the automotive market. Sales are down -9.0% organically and benefited from a positive scope effect of +3.8%.
Scalian generated an EBITDA23 of €54.9 million in 2025. The EBITDA margin rate stood at 10.9%, down by c.30 bps vs. 2024, mainly explained by lower utilization rate, partially offset by strict cost discipline.
As of December 31, 2025, net debt24 stood at €366.9 million (leverage of 6.68x25 EBITDA).
Wendel reinvested c.€100M in Scalian in 2025 to support its external growth (acquisition of Skills&Affinity in 2025) and to strengthen its balance sheet.
Globeducate – Total sales up +10.5%26 over LTM as of November 30, 2025 Year-end. Strong EBITDA margin at 26.0%27 in line with expectations
(equity accounted)
(Globeducate acquisition was completed on October 16th, 2024. For FY 2024 and 2025, contribution of 12 months of sales from December 1st, to November 30th, including India)
Globeducate, one of the world’s leading bilingual K-12 education groups, posted total sales of €415.9 million1 for the full year ending in November 2025, representing a total increase of +10.5% year on year.
EBITDA2 for the year ending in November 2025 amounted to €108.2 million, translating into a strong EBITDA margin of 26.0%, in line with expectations. This solid financial performance was fueled by a combination of organic and external growth.
Over 2025 Globeducate completed 4 acquisitions: Olympion School and Paphos School in Cyprus, and Ecole des Petits in the UK, and Clover in Canada
Net debt28 as of November 30th, 2025, was €826.2 million and leverage29 stood at 7.6x.
Other unlisted assets
Tarkett is valued at the buyout offer price and Muno is classified as an asset held for sale (IFRS 5). The combined value of these two assets in Wendel's NAV as of December 31, 2025 is approximately €200 million.
Consolidated Accounts
On February 25, 2025, Wendel’s Supervisory Board met under the chairmanship of Nicolas ver Hulst and reviewed Wendel’s consolidated financial statements, as approved by the Executive Board on February 20, 2026. The audit procedures by the statutory auditors on the consolidated financial statements are underway. The audit report would be released mid-March 2026.
Wendel Group’s consolidated net sales30 totaled €7,567.9 million, up +6.1% overall and up +5.1% organically. FX contribution is -3.4% and scope effect is +4.4%.
WIM's contribution to net income from operations rose from €42.3 million in 2024 to €127.5 million in 2025 thanks to the acquisition of Monroe Capital in March 2025 and IK Partners' contribution over 12 months in 2025 (compared to 8 months in 2024). WIM's contribution to the net income group share increased from €21.6 million to €79.5 million.
In addition, the total contribution from WPI portfolio companies to net income from operations attributable to the Group amounted to €186.7 million, down 31.9%, mainly due to the reduction in 2025 of Wendel’s stake in Bureau Veritas and weaker results from Stahl and Scalian.
Total financial expenses, general and administrative expenses, and taxes recorded at the level of Wendel SE amounted to €104.9 million (including €24.1 million in non-cash items), representing a sharp increase of 66.5% compared with €63 million in 2024 (including €22.4 million in non-cash items). While general and administrative expenses were slightly lower, net financial income (€-11.5 million in 2025 compared with +€35.6 million in the previous year) no longer benefited from the very significant treasury income recorded in 2024, which resulted from an exceptionally high cash balance during the period and a materially higher average short-term interest rate environment than in 2025.
Net income from operations therefore remained stable at €753.0 million compared with €753.7 million in 2024, while net income from operations attributable to the Group amounted to €161.2 million, down 30.7%.
Consolidated net income for 2025 totaled +€344.7 million (€-151.8 million attributable to the Group), down year on year due to non-recurring items and acquisition-related accounting charges 2024 included a €692 million capital gain on the disposal of Constantia Flexibles. The results of transaction completed in 2025 relating to Bureau Veritas and the increase in the share price of IHS Towers are not recognized in the income statement but in shareholders’ equity, for a positive impact of €1.2 billion.
Supervisory Board composition
At the Shareholders’ Meeting of May 21, 2026, it will be proposed to the shareholders that Franca Bertagnin Benetton and William D. Torchiana be reappointed as independent members of the Supervisory Board for a further four-year term. If the renewal of his mandate is approved, William Torchiana will continue to serve as Chairman of the Governance and Sustainability Committee and as a member of the Audit, Risks and Compliance Committee.
It will also be proposed to the shareholders to appoint Alain Missoffe as a Supervisory Board observer (“censeur”) for a one-year term until the 2027 Shareholders’ Meeting. Alain Missoffe has been appointed as Chair of Wendel-Participations, effective June 4, 2026. He is Managing Director, Group transversal development of Diot-Siaci, a leading French insurance broker.
Agenda
Thursday, April 23, 2026
Q1 2026 Trading update – Financial communication as of March 31, 2026 (before-market release)
Thursday, May 21, 2026
Annual General Meeting
Thursday, July 30, 2026
H1 2026 results – Financial communication as of June 30, 2026, and condensed Half-Year consolidated financial statements (before-market release)
Thursday, October 22, 2026
Q3 2026 Trading update – Financial communication as of September 30, 2026 (before-market release)
Wednesday, December 2, 2026
Investor Day 2026
About Wendel
Wendel is one of Europe’s leading listed investment firms. Regarding its principal investment strategy, the Group invests in companies which are leaders in their field, such as ACAMS, Bureau Veritas, Crisis Prevention Institute, Globeducate, IHS Towers, Scalian, Stahl and Tarkett. In 2023, Wendel initiated a strategic shift into third-party asset management of private assets, alongside its historical principal investment activities. In this context, Wendel completed the acquisitions of a 51% stake in IK Partners in May 2024 and 72% of Monroe Capital in March 2025 and announced the acquisition of Committed Advisors in October 2025. As of December 31, 2025, Wendel Investment Managers manages 47 billion euros on behalf of third-party investors, pro forma of the acquisition of Committed Advisors, and c.5.5 billion euros invested in its Principal Investments activity.
Wendel is listed on Eurolist by Euronext Paris.
Standard & Poor’s ratings: Long-term: BBB, negative outlook – Short-term: A-2
Wendel is the Founding Sponsor of Centre Pompidou-Metz. In recognition of its long-term patronage of the arts, Wendel received the distinction of “Grand Mécène de la Culture” in 2012.For more information: wendelgroup.com
(in millions of euros)20242025ΔOrganic ΔBureau Veritas6,240.96,466.4+3.6%+6.5%Scalian533.4506.0-5.1%-9.0%CPI (1)138.3135.3-2.2%+0.9%ACAMS93.798.8+5.4%+8.6%IK Partners(2)126.5185.7+46.8%n.a.Monroe Capital(3)n.a175.7n.a.n.a.Consolidated sales(4)7,132.97,567.9+6.1%+5.1% (1) In accordance with IFRS 5, the contribution of CPI France has been reclassified in "Net income from discontinued operations and operations held for sale” in 2025 with an impact of €0.4M. Comparable sales for 12M 2024 represent €138.3M versus 2024 published sales of €138.8M. The difference of €0.5M corresponds to CPI France classified as assets held for sale and discontinued operations in accordance with IFRS 5.
(2) Acquisition of IK Partners in May 2024. Contribution of sales for 8 months in 2024 versus 12 months in 2025.
(3) Contribution of 9 months sales from April 1st, 2025 to December 31, 2025
(4) In accordance with IFRS 5, the contribution of Stahl has been reclassified in "Net income from discontinued operations and operations held for sale”
2025 net sales of equity-accounted companies
(in millions of euros)20242025ΔOrganic ΔTarkett (5)3,331.93,346.0+0.4%-0.2%Globeducate (6)n.a415.9n.a n.a Sales (Equity method)3,331.93,762.012.9%-0.5% (5) Selling price adjustments in the CIS countries are historically intended to offset currency movements and are therefore excluded from the
“organic growth” indicator
(6) Contribution of 12 months of sales from December 1st, 2024 to November 30st, 2025 including India
2025 consolidated results
(in millions of euros) 20242025Contribution from asset management42.3127.5Consolidated subsidiaries774.4730.4Financing, operating expenses and taxes-63.0-104.9Net income from operations(1) 753.7753.0Net income from operations, Group share232.7161.2Non-recurring income/loss 561.2-120.9Impact of goodwill allocation-136.8-227.7Impairment-188.2-59.8Total net income(2)989.9344.7Net income, Group share293.9-151.8 (1) Net income before goodwill allocation entries and non-recurring items.
(2) 222.8m€ of change in fair value for IHS and capital gain on prepaid 3-year forward sale and underlying shares sale of the 2026 exchangeable bond into Bureau Veritas shares (+980m€) recognized through OCI
2025 net income from operations
(in millions of euros)20242025ChangeIK Partners 42.364.4 52.0% Monroe Capital n.a63.1 n.aTotal contribution from asset management: 42.3127.5 201.3%Bureau Veritas643.3654.8+1.8%Stahl100.269.6-30.5%CPI22.223.5+5.9%ACAMS-0.7-3.6-437.3%Scalian-6.2-23.3-274.4 %Tarkett (equity accounted)15.615.9+2.0%Globeducate (equity accounted)n.a-6.5n.aTotal contribution from Group companies774.4730.4-5.7%of which Group share274.1186.7-31.9%Operating expenses net of management fees-72.2-68.1-5.7%Taxes-4.0-1.2-69.8%Financial expenses35.6-11.5-132.3%Non-cash operating expenses-22.4-24.1+7.6%Net income from operations753.7753.0-0.1%of which Group share232.7161.2-30.7% Appendix 2: Conversion from accounting presentation to economic presentation
Please refer to table 7.1 of the consolidated statements.
Appendix 3: Loan-to-Value Ratio as of Dec.31, 2025
Dec. 31, 2025Total Assets as of December 31, 2025 (A)7 427 Total cash as of 31/12/20252 200 Bond debt & accrued interest (2 397) IK Parners deffered payments & Monroe earnout (235) Total debt as of Dec. 31, 2025 (2 632) Net debt (B) (432) Spot LTV before restatements (B/A)5.8% Puts related to Monroe acquisition (438) Puts related to Committed Advisors(91)Funds Uncalled Commitments Monroe Capital (90) Funds Uncalled Commitments IK Partners (323) Funds Uncalled Commitments Committed Advisors(162)Post Dec 31, 2025 sales & acquisitions, including SBB784 Total adjustments (C) (320) Adjusted net debt (B+C)(752) S&P LTV as of Dec. 31, 2025 (B+C)/(A+C)9.6% Appendix 4: Glossary
AUM (Assets under Management): Corresponding – for a given fund – to total investors’ commitment (during the fund’s investment period) or total invested amount (post investment period). FRE (Fee-Related Earnings): This indicator is used by Wendel Investment Managers. It corresponds to operating income from third-party asset management activities, excluding Performance Related Earnings (see below). FRE also includes net income from Monroe Capital's Fund O. It does not take into account other financial results, (with the exception of financial income from investment activities), impairment of non-current assets, non-recurring income and expenses (in particular restructuring costs), income and expenses unrelated to the business, entries relating to mergers and acquisitions (in particular gains and losses on disposals, impairment of goodwill allocations, earn-out and deferred payment expenses) and taxes. PRE (Performance Related Earnings): (Performance Related Earnings): this indicator is used by Wendel Investment Managers. It constitutes the variable portion of fees (carried interest allocated to the Group). GP (General Partner): Entity in charge of the overall management, administration and investment of the funds. The GP is paid by management fees charged on assets under management (AuM). 1 FRE Proforma, including Monroe Capital on 12 months
2 Including €340 million in share buybacks for the repurchase of 9% of the capital in 2026 and more than €200 million in dividends for the 2025 financial year.
3 Fully diluted of share buybacks and treasury shares.
4 The acquisition of Committed Advisors is expected to be finalized in the first quarter of 2026.
5 IK Partners and Monroe Capital
6 Closing of the transaction is expected to occur in 2026, subject to IHS shareholder approval, regulatory approvals in the relevant markets, and customary closing conditions.
7 FRE – Fee Related Earnings - pre-tax results generated by management fees.
8 Consolidated FRE, including Committed Advisors acquisition on a full-year basis, with a USD/EUR rate of 1.175. Wendel SE share: approx. €130 million.
9 Based on the IK Partners, Monroe Capital and Committed Advisors scope. At constant exchange rates.
10 GAV excluding cash & other assets.
11 Dividend payout calculated on the basis of fully-diluted NAV at the end of December 2025.
12 Based on Wendel’s share price of €87.95 as of February 25, 2025.
13 LTV calculation explained in Appendix 3.
14 Closed-end fund with a fixed term
15 IK Partners & Monroe Capital
16 Commitments non invested
17 Fee Paying AuM
18 Recurring EBITDA post IFRS 16 excluding French activities. Recurring EBITDA pre IFRS 16 was $74.5m.
19 Post IFRS 16 impact. Net debt pre IFRS 16 impact was $424.5m.
20 EBITDA including IFRS 16. EBITDA excluding IFRS16 stands at $26.0m
21 One time capital expenditures have impacted margins in FY2025, which were higher than in prior years.
22 Including IFRS 16 impacts. Net debt excluding the impact of IFRS 16 was $162.2m.
23 EBITDA including IFRS 16 impact. Excluding IFRS 16, EBITDA stands at €46.2m.
24 Net debt including IFRS 16 impact. Excluding IFRS 16, net debt stands at €334.6m.
25 As per credit documentation (pre IFRS 16).
26 Including Indian activities. Indian estimated revenue stands at €18.9 m in 2025 and €20.9 m in 2024
27 EBITDA including IFRS 16 impacts, including Indian activities in FY 2025. Indian estimated EBITDA stands at €6.7 m.
28 Net debt including IFRS 16 impact. Excluding IFRS 16, net debt stands at €639.8m.
29 As per credit documentation definition.
30 Consolidated sales will be published only for Full Year and Interim results. For Q1 & Q3, sales by companies/activities will continue to be commented on an individual basis
Wendel_EN_FY 2025_
2026-02-26 06:1617d ago
2026-02-26 01:0017d ago
Clariant delivers third year of strong EBITDA margin improvement – EBITDA margin before exceptional items up 180 basis points versus prior year to 17.8 %
Q4 2025 sales increased by 1 % in local currencies1 to CHF 1.028 billion due to strong volume growth in Catalysts and Care ChemicalsQ4 2025 EBITDA margin before exceptional items increased by 240 basis points to 17.1 %, with strong profitability improvement in Catalysts and Care ChemicalsFY 2025 sales of CHF 3.915 billion flat in local currencies1 including 1 % scope (Lucas Meyer Cosmetics) FY 2025 EBITDA margin before exceptional items increased by 180 basis points to 17.8 %, driven by performance improvement programs and cost productivity across the entire organization Performance improvement program achieved CHF 50 million savings in 2025, on track to deliver CHF 80 million with the remainder largely expected in 2026FY 2025 free cash flow conversion of 42 % increased by 10 percentage points, already achieving the medium-term target level Stable distribution of CHF 0.42 per share to be proposed to AGM on 1 April 2026Outlook 2026: local currency sales to be around flat; EBITDA margin before exceptional items at around 18 %; medium-term targets confirmed “In 2025, Clariant delivered an EBITDA margin of 17.8 % before exceptional items, a significant year-on-year increase of 180 basis points. This represents the third consecutive year of EBITDA improvement, both in absolute and margin terms. We achieved this through our performance improvement programs, effective price management, and cost productivity. We made substantial progress in all pillars of our purpose-led growth strategy, including our non-financial and sustainability targets in 2025. With strong execution of our commercial excellence programs, our customer Net Promoter Score (cNPS) increased to 50, placing Clariant in the top quartile among peers. We accelerated the rollout of CLARITY™, our digital service platform designed to optimize catalyst management and performance monitoring, almost doubling the number of users to over 800 in 38 countries. We achieved growth in innovation sales, reaching 18.8 %, reflecting the strength of Clariant's innovation pipeline. Our focus on safety resulted in a Days Away, Restricted, or Transferred (DART) rate of 0.13, significantly down from 2024 and placing Clariant in the top quartile of the chemical industry,” said Conrad Keijzer, Chief Executive Officer of Clariant. “For 2026, we expect sales in local currency to be around flat in a continued challenging market environment, while in addition we offset our portfolio pruning in the prior year. We expect an EBITDA margin of around 18 % before exceptional items,” Conrad Keijzer added.
1 All references to local currency growth, pricing, volumes, and scope exclude the impact from hyperinflation countries Argentina and Türkiye. All references to currency include a net impact from hyperinflation countries Argentina and Türkiye.
Fourth Quarter 2025 Group Figures
MUTTENZ, 26 FEBRUARY 2026
Clariant, a sustainability-focused specialty chemical company, today announced fourth quarter 2025 sales of CHF 1.028 billion, representing an increase of 1 % in local currency1 versus Q4 2024. Pricing was flat, while volumes increased by 1 %. Sales in Swiss francs declined by 6 % year on year due to continued significant currency headwinds.
1 All references to local currency growth, pricing, volumes, and scope exclude the impact from hyperinflation countries Argentina and Türkiye. All references to currency include a net impact from hyperinflation countries Argentina and Türkiye.
Care Chemicals sales increased by 1 % in local currency versus Q4 2024. Pricing was down slightly by 1 % due to formula-based price adjustments linked to raw material costs. Volumes grew by 2 %. Growth was strongest in Mining Solutions and Oil Services, followed by Personal & Home Care. Sales declined slightly in Base Chemicals, followed by Industrial Applications, in a challenging market environment. Crop Solutions came in lower than the prior year, when a restocking effect led to a strong comparison base. Sales in Catalysts increased by 5 % in local currency, driven entirely by higher volumes. Strong growth in Ethylene and Syngas & Fuels more than offset the declines in Specialties and Propylene. Adsorbents & Additives sales decreased by 3 % in local currency, as positive pricing of 1 % did not offset 4 % lower volumes.
Group EBITDA before exceptional items of CHF 176 million increased by 10 % year on year with the corresponding margin of 17.1 % representing a 240-basis points improvement versus 14.7 % in the prior year. This was the result of continued strong execution of the performance improvement programs in all business units, effective cost management, a positive mix with strong growth in Catalysts, and operating leverage. Strong pricing management in a deflationary raw material environment (- 2 %) contributed positively to profitability and offset higher energy costs (+ 4 %).
Key measures to deliver the targeted CHF 80 million savings from the performance improvement program (Investor Day 2024) by 2027 were successfully implemented and contributed CHF 19 million in the fourth quarter. Cost-efficient execution of the program meant that no additional restructuring charges were booked during the quarter.
Reported EBITDA for the Group increased by 8 % to CHF 193million. EBITDA margin of 18.8 % increased by 240 basis points versus 16.4 % reported in the fourth quarter of 2024. Positive one-off gains from portfolio pruning measures positively contributed to the reported EBITDA.
Full Year 2025 Group Figures
In the full year 2025, sales of CHF 3.915 billion were flat in local currency1 and declined by 6 % in Swiss francs. Pricing was flat, while volumes were down 1 %. Scope had a positive impact of 1 %, reflecting the contribution of Lucas Meyer Cosmetics by Clariant. The currency impact of - 6 % was driven by movements in the US dollar, Indian rupee, Brazilian real, Euro, and Chinese yuan.
1 All references to local currency growth, pricing, volumes, and scope exclude the impact from hyperinflation countries Argentina and Türkiye. All references to currency include a net impact from hyperinflation countries Argentina and Türkiye.
Care Chemicals sales were flat in local currency. Pricing was stable, while organic volumes declined by 1 % and the acquisition of Lucas Meyer Cosmetics contributed 1 % to scope. Growth was strongest in Crop Solutions, followed by Mining Solutions and Personal & Home Care. Industrial Applications had the most pronounced decline during the year as customer demand was impacted by overall market uncertainty, including tariffs. In Catalysts, sales decreased by 2 % in local currency as a result of stable pricing and lower volumes. Growth in Ethylene catalysts and Syngas & Fuels did not entirely offset declines in Propylene and Specialties. Adsorbents & Additives sales were flat in local currency, with pricing up 1 % and volumes down 1 %. Sales growth in Additives offset a decline in Adsorbents.
Group EBITDA before exceptional items increased by 5 % against the prior year to CHF 697 million, while the corresponding margin increased by 180 basis points to 17.8 % and was driven by performance improvement programs and cost productivity across all Business Units and Corporate functions. Strong pricing management against slightly deflationary raw material costs (- 1 %) supported the margin improvement.
Key measures to deliver the targeted CHF 80 million savings from the performance improvement program (Investor Day 2024) by 2027 were successfully implemented and cumulatively contributed CHF 50 million in 2025. These include announced headcount reductions, the closure of two sites and two production lines, and procurement savings related to structural changes in qualifying alternative suppliers and best-practice contract management. We recorded CHF 63 million of restructuring charges in 2025 versus an expected CHF 75 million as a result of cost-efficient execution and phasing.
Reported EBITDA for the Group declined by 2 % to CHF 643 million. The CHF 63 million restructuring charges booked during the year were partially offset by one-off gains from the portfolio pruning measures. Reported EBITDA margin of 16.4 % increased by 60 basis points compared to 2024.
Group EBIT for the full year 2025 decreased to CHF 362 million from CHF 440 million in the prior year due to lower sales, restructuring charges of CHF 63 million and impairments of CHF 29 million related to the portfolio pruning.
In the full year 2025, the Group recorded a net loss of CHF 41 million versus a net income of CHF 280 million in the prior year. This was largely due to a non-cash cumulative translation adjustment (CTA) of CHF 230 million, stipulated by IFRS following the divestment of the Group’s operations in Venezuela. Adjusted for that exceptional accounting effect, the Group’s net income was CHF 189 million.
Net cash generated from operating activities for the total Group was stable at CHF 419 million versus CHF 418 million in the prior year. Disciplined capital expenditure supported the increase in free cash flow of CHF 64 million to CHF 273 million, compared to CHF 209 million in 2024. The free cash flow conversion rate of 42 % for the full year 2025 represents a significant improvement versus the 32 % achieved in the prior year and delivers on the medium-term target of a conversion rate of around 40 %.
Net debt for the total Group decreased to CHF 1.413 billion versus CHF 1.489 billion recorded at the end of 2024 due to improved cash generation. The resulting net debt to EBITDA before exceptional items ratio stood at 2.03x at the end of 2025. This was an improvement compared to 2.25x recorded in the prior year and indicates the company’s commitment to maintaining its investment grade rating.
The Board of Directors recommends a regular distribution to shareholders of CHF 0.42 per share to the Annual General Meeting (AGM) on 1 April 2026 based on Clariant’s performance in 2025. This distribution is proposed to be made through a capital reduction by way of a par value reduction.
The Board of Directors proposes the reelection of Ben van Beurden as Chairman. Following the Board’s decision to reduce its size from eleven to eight members and enhance corporate governance, Roberto Gualdoni, Geoffery Merszei, Eveline Saupper, Peter Steiner, and Konstantin Winterstein will not stand for reelection at the AGM. The Board of Directors has proposed to newly elect Regula Wallimann and Albert Manifold to the Clariant Board, while Claudia Suessmuth Dyckerhoff, Susanne Wamsler, Ahmed Mohammed Al Umar, Jens Lohmann, and Thilo Mannhardt all stand for reelection. The Clariant Integrated Report 2025 will be published on 27 February 2026.
Outlook 2026
For the full year 2026, Clariant expects macroeconomic challenges, uncertainties, and risks to remain. Clariant therefore expects sales in local currency to be around flat as the company looks to offset a negative top-line impact for the Group of 1 % (2 % in Care Chemicals) from its portfolio pruning in the prior year. Slight growth is expected in Care Chemicals (underlying) and Adsorbents & Additives, while sales in Catalysts are expected to be at levels similar to those of 2025.
Clariant expects an EBITDA margin before exceptional items of around 18 % in 2026. The CHF 80 million performance improvement program, as announced during the company’s Investor Day in November 2024, is expected to deliver most of the remaining cost savings during the year, after CHF 50 million savings were achieved in 2025. Clariant also expects to continue to achieve a free cash flow conversion of around 40 % in 2026.
Clariant reiterates its commitment to its medium-term targets, to be achieved by 2027 at the latest: 4 – 6 % local currency sales growth (in a normalized market of 2 – 4 %); 19 – 21 % reported EBITDA margin; and around 40 % free cash flow conversion.
Substantial progress on all pillars of Clariant’s purpose-led growth strategy
Clariant achieved substantial progress in executing its purpose-led growth strategy centered on "Greater chemistry – between people and planet". Built on four strategic pillars – customer focus, innovative chemistry, leading in sustainability, and people engagement – the strategy reflects Clariant's integrated approach to creating value for all stakeholders. By shaping the future alongside customers, accelerating innovation that expands what is possible, leading the transition toward sustainability, and building a culture of possibilities that empowers every individual, Clariant is driving transformative change across the chemical industry while balancing business growth with environmental responsibility and social impact.
With a strong execution of our commercial excellence programs, Clariant delivered a further improvement in the satisfaction of its customers, measured by the customer Net Promoter Score (cNPS). In 2025, this cNPS increased to 50 in 2025 versus 45 in 2024, with the company receiving outstanding scores for “product quality,” “technical support,” and “customer service.” Overall, this score placed Clariant in the top quartile among peers.
Clariant successfully accelerated the rollout of CLARITY™, its digital service platform designed to optimize catalyst management and performance monitoring. This solution provides customers with real-time data analytics, predictive maintenance capabilities, and operational insights to maximize the efficiency and lifespan of catalysts used in industrial processes. CLARITY™ helps customers make data-driven decisions about their catalyst operations, ultimately improving plant productivity, reducing downtime, and enhancing overall process economics. By the end of 2025, CLARITY™ has onboarded over 220 customer plants and over 800 users in 38 countries, compared to over 120 customer plants and 450 users in 28 countries at the time of the Investor Day in 2024.
Clariant demonstrated strong improvement in innovation sales, reaching 18.8 %, marking a significant rebound from the 16.9 % recorded in 2024. This trajectory reflects the strength of Clariant’s innovation pipeline. The company maintained its commitment to research and development with sustained investments of 3 % of sales in 2025. This dedication to innovation was further validated by customers and industry associations through multiple awards and recognitions received throughout the year.
Clariant’s Scope 1 & 2 total greenhouse gas (GHG) emissions fell to 0.43 million metric tons in 2025, a decline of 11 % from 0.49 million metric tons in the full year 2024. The main driver for the GHG reduction in 2025 was a continued transition to green electricity. The share of renewable electricity increased from 69 % to 76 % due to green electricity supply contracts and improved market-based emission factors of selected suppliers. The total indirect greenhouse gas emissions for purchased goods and services (Scope 3.1) were 6 % lower at 2.41 million metric tons in the last twelve months, compared to 2.58 million metric tons in the full year 2024, supported by transformative actions at suppliers and lower volumes.
In 2025, Clariant achieved leadership-level scores across all environmental categories of the Carbon Disclosure Project (CDP), which is one of the most widely used environmental disclosure platforms globally. Ranking in the top 1 % of all companies evaluated worldwide, Clariant was awarded “A” for Climate Change and Forests, and “A-“ for Water Security. These leading scores demonstrate decisive progress over time, credible targets, verified data, and clear accountability at the top.
In 2025, Clariant also achieved a DART (Days Away, Restricted, or Transferred) rate of 0.13, down from 0.17 in 2024. This result places Clariant in the top quartile of the chemical industry globally and reflects the high awareness of and continued commitment to safety, training, and accountability.
In January 2026, Clariant invited all employees to participate in the annual engagement survey. The participation rate increased to 88 %, compared to 86 % in 2025. Meaningful progress has been achieved in the Employee Engagement which at 87 % positions Clariant in the top quartile, compared to relevant industry peers. Continuous improvement was achieved in the Employee Net Promoter Score (eNPS), increasing from + 34 in 2025 to + 37 in 2026.
In the fourth quarter of 2025, sales in the Business Unit Care Chemicals increased by 1 % in local currency and decreased by 6 % in Swiss francs versus Q4 2024. Pricing was down 1 % due to formula-based price adjustments in industrial segments linked to raw material costs. Volumes grew by 2 %.
Growth was strongest in Mining Solutions, driven entirely by volumes, and Oil Services, where higher volumes were supported by slightly positive pricing. Sales in Personal & Home Care increased slightly, also driven by volume growth and including a continued positive contribution from Lucas Meyer Cosmetics and capacity expansion in China. Base Chemicals declined slightly, despite volume growth in the seasonal Aviation business, as pricing declined due to the formula-based price adjustments linked to raw material costs. Sales in Industrial Applications declined due to lower pricing and volumes. Crop Solutions declined, driven by lower volumes in comparison to the prior year, when a restocking effect led to strong growth.
Care Chemicals sales in the Europe, Middle East & Africa region decreased at a mid-single-digit percentage rate as weakness in Germany continued. In the Americas, sales grew at a low single-digit percentage rate due to resilient demand in the United States. Sales in Asia-Pacific increased at a high single-digit percentage rate as the capacity expansion in Daya Bay, China, drove local volume growth.
In the full year 2025, sales in the Business Unit Care Chemicals were flat in local currency (- 1 % excluding scope) and decreased by 6 % in Swiss francs. Crop Solutions showed the strongest growth, followed by Mining Solutions and Personal & Home Care. Lucas Meyer Cosmetics (+ 1 % scope) continued its positive trajectory, driven by innovation.
EBITDA Margin
In the fourth quarter of 2025, EBITDA before exceptional items increased by 7 % to CHF 96 million. EBITDA before exceptional items margin improved by 220 basis points to 18.3 % from 16.1 % in the prior year due to increased operating leverage and strong contribution from the performance improvement program. Raw material costs declined by 2 %, while energy costs increased by 5 %.
Reported EBITDA of CHF 109 million increased by 21 % compared to the prior year period. The corresponding margin improved by 470 basis points to 20.8 % from 16.1 % in Q4 2024, when weaker seasonal business, inventory management, and higher maintenance weighed on profitability. The improvement was supported by positive one-off gains from portfolio pruning.
EBITDA margin before exceptional items for the full year 2025 increased by 100 basis points to 19.3 % from 18.2 % in the prior year. Reported EBITDA decreased to CHF 386 million from CHF 403 million, including CHF 29 million of restructuring charges, while the corresponding margin increased by 30 basis points to 18.3 % from 18.0 %.
In the fourth quarter of 2025, sales in the Business Unit Catalysts increased by 5 % in local currency and decreased by 2 % in Swiss francs. While pricing was flat, volumes grew by 5 %.
Sales in Ethylene catalysts recorded the strongest growth at a high double-digit percentage rate, with some first-fill business coming on top of the regular refill cycle, followed by Syngas & Fuels. This more than offset lower sales in Specialties and Propylene, which both declined at a double-digit percentage rate against a strong comparison base in the prior year.
Sales decreased at a high single-digit percentage rate in the Europe, Middle East & Africa region, driven by a decline in Germany. Sales in the Americas increased at a high double-digit percentage rate due to project deliveries in the United States. In Asia-Pacific, the largest geographic market, sales decreased at a low single-digit percentage rate, as growth in the region did not entirely compensate for lower sales in China.
In the full year 2025, sales in the Business Unit Catalysts decreased by 2 % in local currency and by 8 % in Swiss francs. Growth in Ethylene and Syngas & Fuels catalysts did not offset declines in Specialties and Propylene. This decline was entirely driven by lower volumes due to anticipated weak new-built activities in the industry and shifts in the regular refill cycles due to low utilization rates of production facilities.
EBITDA Margin
In the fourth quarter, EBITDA before exceptional items increased by 22 % to CHF 62 million, representing a margin of 23.4 %. This 460-basis point improvement against the 18.8 % margin of the prior year was driven by improved operating leverage and contribution from the performance improvement program. Raw material prices were up 1 %, while energy prices were up 4 % versus the prior year.
Reported EBITDA of CHF 60 million decreased by 12 % compared to the prior year. The corresponding margin of 22.6 % decreased versus 25.1 % recorded in the prior year, when a reversal of provisions lifted the reported number.
EBITDA margin before exceptional items for the full year 2025 increased to 20.8 % from 17.4 % in the prior year due to effective price and cost management and contributions from performance improvement programs. Reported EBITDA was CHF 164 million compared to CHF 174 million in the prior year, with the corresponding margin increasing by 40 basis points to 20.1 % from 19.7 %. Restructuring charges of CHF 6 million were recognized in 2025.
In the fourth quarter of 2025, sales in the Business Unit Adsorbents & Additives decreased by 3 % in local currency and by 8 % in Swiss francs. In the Adsorbents segments, sales decreased at a low single-digit percentage rate, impacted by lower demand in renewable fuels. In the Additives segments, sales decreased at a mid-single-digit percentage rate, mainly driven by Coatings & Adhesives (construction). For the business unit, pricing was up 1 %, while volumes were down 4 %.
In the Europe, Middle East & Africa region, the largest geographic market, sales decreased at a mid-single-digit percentage rate. In the Americas, sales decreased at a high single-digit percentage rate, as growth in Additives did not fully offset a decline in Adsorbents with volumes impacted by delayed US renewable fuel regulation. Asia-Pacific sales increased at a mid-single-digit percentage rate.
In the full year 2025, sales in the Business Unit Adsorbents & Additives were flat in local currency and decreased by 4 % in Swiss francs, as the continued improvement in Additives was offset by weakness in Adsorbents.
EBITDA Margin
In the fourth quarter, EBITDA before exceptional items decreased by 9 % to CHF 30 million, representing a margin of 12.6 %, thus at a similar level to the 12.7 % recorded in the prior year. The positive contribution from the performance improvement program partly offset the impact of lower volumes. Lower raw material prices (- 4 %) contributed positively, while higher energy prices (+ 4 %) weighed on profitability.
The reported EBITDA of CHF 32 million decreased by 6 % compared to the prior year, with a corresponding margin of 13.4 % compared to 13.1 % in the prior year due to lower restructuring costs.
EBITDA margin before exceptional items for the full year 2025 increased by 130 basis points to 17.1 % from 15.8 % in the prior year, supported by positive pricing and contributions from the performance improvement programs. Reported EBITDA increased to CHF 158 million from CHF 155 million, with the corresponding margin increasing to 16.0 % from 15.1 %. Restructuring charges of CHF 15 million were recognized in 2025.
Group Key Financial Figures
Fourth Quarter Full Yearin CHF million20252024% CHF% LC(1)20252024% CHF% LC(1)Sales1 0281 091- 613 9154 152- 60EBITDA1931798 643657- 2 - margin18.8 %16.4 % 16.4 %15.8 % EBITDA before exceptional items17616010 6976635 - margin17.1 %14.7 % 17.8 %16.0 % EBIT 362440 Return on invested capital (ROIC) 6.9 %9.2 % Net income total - 41280 Net cash generated from operating activities 419418 Number of employees (FTE) 10 28110 465 (1) Excluding hyperinflation accounting countries Argentina and Türkiye
This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.
www.clariant.com
Clariant is a focused specialty chemical company led by the overarching purpose of “Greater chemistry – between people and planet.” By connecting customer focus, innovation, and people, the company creates solutions to foster sustainability in different industries. On 31 December 2025, Clariant totaled a staff number of 10 281 and recorded sales of CHF 3.915 billion in the fiscal year. Since January 2023, the Group conducts its business through the three Business Units Care Chemicals, Catalysts, and Adsorbents & Additives. Clariant is based in Switzerland.
2026-02-26 06:1617d ago
2026-02-26 01:0117d ago
CMB.TECH ANNOUNCES Q4 2025 RESULTS - EIGHT VLCCS SOLD AT STELLAR PRICES
CMB.TECH ANNOUNCES Q4 2025 RESULTS
EIGHT VLCCS SOLD AT STELLAR PRICES
ANTWERP, Belgium, 26 February 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the fourth quarter ended 31 December 2025.
HIGHLIGHTS
Financial highlights: Profit for the period of USD 90.1 million in Q4 2025. EBITDA for the same period was USD 322 million.CMB.TECH’s contract backlog increased by USD 304 million to USD 3.05 billion with the addition of 5 x 5-year charters for Capesizes and a 3-year contract for a CSOV.Declaration of an interim dividend of USD 0.16 per share.Over the course of Q4 2025 and Q1 2026, the company has fully repaid the bridge loan facility that was originally raised to finance the acquisition of a large stake in Golden Ocean Fleet highlights:
Delivery of 6 newbuilding vessels (Q4 + quarter to date): VLCCs: Atrebates, EburonesChemical tankers: Bochem CallaoCSOV: Windcat AmsterdamCTV: FRS Windcat 62, FRS Windcat 61 Previously announced sale of 8 VLCCs: Daishan (2007, 306,005 dwt), Hirado (2011, 302,550 dwt), Ilma (2012, 314,000 dwt), Ingrid (2012, 314,000 dwt), Hojo (2013, 302,965 dwt), Dia (2015, 299,999 dwt), Antigone (2015, 299,421 dwt), and Aegean (2016, 299,999 dwt).Previously announced sale of Capesize vessels Golden Magnum (2009, 179,790 dwt), and Belgravia (2009, 169,390 dwt). Corporate highlights:
Sale of stake in Tankers International Pool, closed on 27 January 2026.CMB.TECH is investing in the Chinese ammonia supply chain.Management Board changes: resignation of Mr. Benoit Timmermans For the fourth quarter of 2025, the company realised a net gain of USD 90.1 million or USD 0.31 per share (fourth quarter 2024: a net gain of USD 93.1 million or USD 0.48 per share). EBITDA (a non-IFRS measure) for the same period was USD 322.1 million (fourth quarter 2024: USD 180.4 million).
Commenting on the Q4 results, Alexander Saverys (CEO) said:
“Tanker markets continue to defy gravity due to a mix of shifting trade patterns, modest newbuilding deliveries and a particularly active tanker owner/operator who is adding fuel to the fire. Dry bulk freight rates have also held up very well during Q4 and well into Q1. With two CSOVs delivered to our fleet, we are starting to generate meaningful cash flows in the offshore supply markets. The versatile nature of our ships allows us to serve wind and oil and gas customers alike.
We have used this very strong market back-drop to sell some of our older vessels at stellar prices, and fixed multiple long-term charter contracts at attractive rates. We will use the proceeds to decrease our leverage, strengthen our balance sheet and pay dividends. The repayment of the Golden Ocean bridge – less than six months after the merger – is testimony to our capability to execute large transactions swiftly, efficiently and in a disciplined manner.”
Key figures
The most important key figures (unaudited) are: (in thousands of USD) Fourth Quarter 2025 Fourth Quarter 2024 YTD 2025 YTD 2024 Revenue 589,123 226,029 1,666,223 940,246 Other operating income 1,361 8,254 29,613 50,660 Raw materials and consumables (3,769) (1,576) (10,265) (3,735) Voyage expenses and commissions (128,169) (42,692) (362,155) (174,310) Vessel operating expenses (128,067) (52,817) (420,409) (199,646) Charter hire expenses (415) (3) (3,124) (138) General and administrative expenses (52,813) (24,616) (143,284) (77,766) Net gain (loss) on disposal of tangible assets 49,489 71,114 192,564 635,017 Depreciation and amortisation (114,526) (43,911) (387,968) (166,029) Impairment losses (2,081) (1,847) (5,354) (1,847) Net finance expenses (110,997) (47,096) (404,630) (130,650) Share of profit (loss) of equity accounted investees (2,599) (1,418) (882) 920 Result before taxation 96,537 89,421 150,329 872,722 Income tax benefit (expense) (6,476) 3,709 (10,185) (1,893) Profit (loss) for the period 90,061 93,130 140,144 870,829 Attributable to: Owners of the Company 90,061 93,130 161,698 870,829 Non-controlling interest — — (21,554) — Earnings per share: (in USD per share) Fourth Quarter 2025 Fourth Quarter 2024 YTD 2025 YTD 2024 Weighted average number of shares (basic) * 290,169,769 194,216,835 229,443,392 196,041,579 Basic earnings per share 0.31 0.48 0.61 4.44 The number of shares issued on 31 December 2025 is 315,977,647. However, the number of shares excluding the owned shares held by CMB.TECH at 31 December 2025 is 290,169,769. EBITDA reconciliation (unaudited): (in thousands of USD) Fourth Quarter 2025 Fourth Quarter 2024 YTD 2025 YTD 2024 Profit (loss) for the period 90,061 93,130 140,144 870,829 + Net finance expenses 110,997 47,096 404,630 130,650 + Depreciation and amortisation 114,526 43,911 387,968 166,029 + Income tax expense (benefit) 6,476 (3,709) 10,185 1,893 EBITDA (unaudited) 322,060 180,428 942,927 1,169,401 EBITDA per share: (in USD per share) Fourth Quarter 2025 Fourth Quarter 2024 YTD 2025 YTD 2024 Weighted average number of shares (basic) 290,169,769 194,216,835 229,443,392 196,041,579 EBITDA 1.11 0.93 4.11 5.97 All figures, except for EBITDA, have been prepared under IFRS as adopted by the EU (International Financial Reporting Standards) and have not been audited nor reviewed by the statutory auditor.
During the quarter, several nonrecurring items affected the company’s financial performance. The company fully repaid the bridge loan facility that had originally been raised to finance the acquisition of a large stake in Golden Ocean, resulting in a one-off charge of USD 13.6 million, mainly related to arrangement and success fees. Furthermore, following the various refinancings completed in Q4 (which included a repayment of more than USD 700 million under the USD 2 billion facility) approximately USD 11 million in arrangement fees were expensed. In addition, 28 reflagging operations were carried out in Q4, temporarily increasing operating expenses by approximately USD 2.9 million. Reflagging of vessels is required in view of the contemplated cross-border merger of CMB.TECH Bermuda (holding company of ex-Golden Ocean group) with CMB.TECH Belgium. Other non-recurring costs (SG&A and tax) accounted for USD 15 million.
Interim dividend
CMB.TECH has declared an interim dividend of USD 0.16 per share, which is expected to be paid on or about 27 April 2026.
The timing of the distribution of this interim dividend is as follows:
COUPON 44Ex-dividend dateRecord datePayment dateEuronext14 April 202615 April 202622 April 2026NYSE15 April 202615 April 202622 April 2026OSE14 April 202615 April 2026On or about 27 April 2026 TCE
The average daily time charter equivalent rates (TCE, a non IFRS-measure) can be summarised as follows:
Q4 2025Q4 2024Quarter-to-Date Q1 2026USD/dayUSD/dayUSD/dayFixed %DRY BULK VESSELSNewcastlemax average spot rate(1)34,88629,80030,67380.0%Newcastlemax average time charter rate21,284 Capesize average rate(1)30,137 26,72572.0%Panamax/Kamsarmax average spot rate(1)17,337 13,27966.0%Panamax/Kamsarmax average time charter rate13,207 TANKERSVLCC average spot rate (2)74,84237,40074,46578.0%VLCC average time charter rate(3)45,58246,300 Suezmax average spot rate(1) (3)64,54338,30061,80987.0%Suezmax average time charter rate33,61331,800 CONTAINER VESSELSAverage time charter rate29,37829,378 CHEMICAL TANKERSAverage spot rate(1) (2)20,88724,500 17,878 N/AAverage time charter rate19,30619,306 OFFSHORE WINDCSOV Average time charter rate108,046 69,90050.0%CTV Average time charter rate2,8832,9002,47268.8% 1) Reporting load-to-discharge, in line with IFRS 15, net of commission
(2) CMB.TECH owned ships in TI Pool or Stolt Pool (excluding technical off hire days)
(3) Including profit share where applicable
CORPORATE UPDATE
Sale TI Pool
CMB.TECH has sold its share in the Tankers International (TI) Pool to International Seaways (INSW), closed on 27 January 2026. Our tanker division Euronav was one of the founding fathers of TI and has supported the company throughout its successful history. With the sale of a large part of our VLCC fleet to Frontline in 2024 and the recent sale of some older tankers more recently, it was the right moment to exit TI. Under the new full ownership of INSW, the company and its employees will remain a strong reference in the crude oil tanker markets.
Andefu
CMB.TECH previously announced that the company is investing in the Chinese ammonia supply chain. CMB.TECH has signed an off-take agreement for green ammonia produced by CEEC Hydrogen Energy (“CEEC”) in Jilin Province and owns a minority share in privately owned Jiangsu Andefu Energy Technology Co., Ltd. (“Andefu”) one of China's largest ammonia supply chain companies. This creates an industrial partnership between two companies supporting maritime decarbonisation and the development of a green ammonia supply infrastructure.
A subsidiary of Andefu, Jiangsu Andefu Storage Co., Ltd., is currently constructing a 49,000 m³ low-temperature ammonia storage tank in Nanjing, providing critical hub capacity for ammonia distribution and future marine fuel applications. The storage tank is scheduled to be commissioned in Q1 2026. In addition, Andefu, in cooperation with CEEC, will build an ammonia storage terminal into operation in Panjin in the second half of 2027, significantly enhancing China’s large-scale green ammonia logistics and supply capabilities. Andefu is also advancing ship-to-ship (STS) ammonia bunkering operations, targeting commercial deployment in 2026, to support the emerging global ammonia-fuelled shipping fleet together with CMB.TECH.
Golden Ocean bridge
Over the course of Q4 2025 and Q1 2026, the company has fully repaid the bridge loan facility that was originally raised to finance the acquisition of a controlling stake in Golden Ocean while continuing the integration workstreams related to the Golden Ocean merger. This resulted in a one‑off charge of USD 13.6 million, primarily reflecting arrangement and success fees. No additional costs related to these activities are anticipated in the 2026 financial year. The early repayment in full of the USD 1.4 billion Golden Ocean bridge loan facility is projected to yield approximately USD 41.9 million in interest savings over the 2026 reporting period.
Management Board change
Mr. Benoit Timmermans has decided to resign as member of the Management Board of CMB.TECH with effect as of 1 May 2026. Mr. Benoit Timmermans joined the Management Board of CMB.TECH as Chief Strategy Officer and has assisted the company in the transition from a pure-play crude oil tanker player to a large and diversified maritime group. For the time being, Mr. Timmermans will not be replaced. His responsibilities will be taken over by the current members of the Management Board.
CMB.TECH FLEET DEVELOPMENTS
Commercial contracts
CMB.TECH’s contract backlog increased by USD 304 million to USD 3.05 billion:
5 Capesizes were fixed for charter contracts of 5 years each. These will commence in the coming months.
Mineral Ajisai (2014, 180,600 dwt)Mineral Sakura (2014, 182,480 dwt)Mineral Cumulus (2018, 180,600 dwt)Mineral Calvus (2018, 180,520 dwt)Mineral Incus (2018, 180,510 dwt) The CSOV Windcat Amsterdam was fixed for 3 years as from 1 April 2026.
Sales
Following vessels were delivered to new owners in Q4 2025 - generating a total capital gain of approximately USD 49.2 million:
VLCC Dalma (2007, 306,543 dwt) – capital gain of USD 26.4 million Capesize Battersea (2009, 169,390 dwt) – capital gain of USD 2.4 millionCapesize Golden Zhoushan (2011, 175,834) was delivered to its new owner during Q4 2025 – no capital gain Suezmax Sofia (2010, 165,000 dwt) – capital gain of USD 20.4 million Following vessels will be delivered to new owners in Q1 2026:
Capesize vessels Golden Magnum (2009, 179,790 dwt), and Belgravia (2009, 169,390 dwt) - capital gain of approximately USD 8.1 million in Q1 2026, based on the net sales price and book valuesSix VLCCs: Daishan (2007, 306,005 dwt), Hirado (2011, 302,550 dwt), Hojo (2013, 302,965 dwt), Dia (2015, 299,999 dwt), Antigone (2015, 299,421 dwt), and Aegean (2016, 299,999 dwt) - capital gain of approximately USD 261.1 million in Q1 2026, based on the net sales price and book values. Following vessels will be delivered to new owners in Q2 2026:
Two VLCCs: Ilma (2012, 314,000 dwt) and Ingrid (2012, 314,000 dwt) - capital gain of approximately USD 98.2 million in Q2 2026, based on the net sales price and book values. Newbuilding deliveries
Delivery dateType of vesselName10 November 2025VLCCAtrebates (2025, 319,000 dwt)12 November 2025CTVWindcat 6112 December 2025CTVWindcat 6219 December 2025CSOVWindcat Amsterdam12 January 2026VLCCEburones (2026, 319,000 dwt)13 January 2026Chemical tankerBochem Callao (2026, 25,000 dwt) MARKET & OUTLOOK
Bocimar – Dry-Bulk Market1
Following a slow first half in 2025, imports of iron ore to mainland China rebounded strongly in H2 2025, ending the year at 1,327 million tonnes, driven by stockpiling, a strengthening yuan which made imports more cost-effective, and targeted stimulus aimed at stabilising construction and manufacturing activity. The expansion was primarily fuelled by heightened trade flows between major iron ore producing regions and key consuming markets: Australia, Brazil, Sub-Saharan Africa, and Canada significantly increased shipments to mainland China, while Brazil and Oman boosted their shipments to India, and Liberia expanded its supply to Europe. Chinese steel exports also hit a record 11.3 million tons in December 2025, raising for the full year by 7.5% to 119.2 million tons. Capesize spot earnings in Q4 2025 averaged about 27,120 USD/day (34% higher than the 10-year Q4 average). Panamax spot earnings in Q4 2025 averaged about 14,880 USD/day (6% below the 10-year Q4 average).
In China, portside inventories are on a raising trend, reaching 151.6 million tonnes by the end of 2025, just below all-time highs. While elevated stocks can slow the rhythm of spot cargoes as mills draw down port inventories first, the iron ore market remains fundamentally supported. Despite sustained policy initiatives aimed at improving domestic resource security, China’s local iron-ore mines continue to fall short of official production objectives. Output of iron-ore concentrate decreased y-o-y 2025 by 3.2%. This decline underlines persistent challenges, including diminishing ore grades, fragmented industry ownership, and slow rates of capital investment. China’s domestic ore, with its low iron content and high impurities, cannot meet the requirements of modern blast-furnace operations on its own. To achieve stable furnace performance, steelmakers blend higher-grade imported fines with domestic material – raising the effective grade, improving fuel efficiency, and supporting consistent output. Hence, high-grade seaborne imports of iron ore are essential for keeping China’s steel production efficient, cost-effective, and technically reliable. In addition, on the steel side, the introduction of export licensing from 1 January 2026 marks a clear change in how outbound steel trade is managed and exports switched from quantity to quality. Higher quality steel exports further reconfirm the requirement of seaborne high-grade iron ore sourcing and hence also further support the ton-mile story for the Capesize and Newcastlemax segment.
Structurally longer trade flows and high-grade substitution support tonne-mile demand. The ramp-up of the Simandou project in Guinea—targeting 120 million tonnes/year by 2028—will introduce high-grade ore flows (65% Fe) that are structurally longer than Australia-to-China shipments. Initial deliveries of 200,000 tonnes have already reached China, with total 2026 production expected at 15–20 million tonnes. Next to Simandou, South Buchanan/Liberia (Mittal) will increase iron ore exports from 5 to15 million tonnes in 2026.
Overall, iron ore discharge to mainland China in 2026 is projected to rise to 1,361 million tonnes (up 2.5% y-o-y), underpinned by supportive fiscal and monetary policies, a strong yuan, and declining domestic output. However, there is potential for reduced shipments in the first quarter of 2026, as demand from Chinese steel mills may soften during the Lunar New Year holiday. Global seaborne iron ore shipments are projected to increase by 1.9% y-o-y in 2026, reaching 1,799 million tonnes.
Bauxite has become an increasingly important cargo stream for Capesize vessels (roughly 16% of Capesize tonne-mile demand), offsetting weakness in coal volumes. Guinea’s bauxite shipments have been outperforming its historical volumes, with 47 million tonnes shipped in Q4 2025, up approximately 7 million tonnes y-o-y, with 91% of the volume shipped to mainland China. We expect this buoyancy to persist in 2026, even though with a lesser degree, with Q1 2026 volume to be up 3 million tonnes y-o-y from Guinea. Mainland China’s bauxite arrivals are expected to expand by 9 million tonnes during the year in line with the increased domestic demand for inputs feeding into the aluminium industry. However, this is considerably less than the 40 million tonnes surge experienced in 2025. Domestic bauxite inventories have been historically high along with an oversupply of alumina and with the government mandated production cap on aluminium at 45 million tonnes, the expected increase in additional bauxite demand will likely moderate relative to last year. However, notably, capacity expansion at Chinese-owned Chalco-Boffa Mining site in Guinea should continue facilitating additional supply between the two trade partners.
While bauxite and iron ore continue to be positive contributors to the dry bulk market, the coal trade is trending in the opposite direction. Demand from mainland China for thermal coal took a hit over 2025 as the expansion in renewable capacity and generation increasingly ate into coal-fired generation, and rising domestic output displaced seaborne supply. We may have already seen the peak of coal consumption in mainland China as over 2025 we have seen coal-fired generation drop, as the growth in electricity generation takes on a more restrained pace and renewable additions continue their fierce 25-30% y-o-y growth rate. The outlook for the beginning of 2026 remains flat, as the market remains fundamentally weak in terms of coal demand, save for some import activity from buyers in mainland China looking to fulfil their requirements for the colder than expected winter months.
Agribulk shipments rose 2.5% y-o-y 2025 followed by a 1.5% growth expected in 2026. US shipments are expected to rise on the back of healthy corn production in addition to revival in soybean trade with mainland China (revival after interruption of exports since May due to tariff war). In Q1 2026 to date, an early start to grain season has supported the Kamsarmax market which in turn supports the other dry bulk segments during the low season
The Capesize and Newcastlemax orderbook currently stands at 12.4% of the active fleet. 36% or 586 vessels are over 15 years old and are increasingly uneconomical to operate amid rising environmental compliance costs. The Panamax and Kamsarmax orderbook currently stands at 15.16% – with 32% or 900 vessels over 15 years old. The market remains relatively balanced, though growth drivers are strongly skewed in favour of Capesizes: estimated demand growth in 2026 of 2.7%, in billion tonne miles with a net fleet growth of 2.3%. (Panamax estimated demand growth in 2026 of 3.2%, in billion tonne miles with a net fleet growth of 4.7%)
Bocimar has 36 (+10NB) Newcastlemaxes on the water (average age 3.2y), 37 Capesize vessels on the water (average age 11.2), 30 Kamsarmax/Panamax vessels on the water (average age 6.9y), and two 5,000 dwt dry-bulk coasters on order.
Q4 2025 Performance Highlights:
Newcastlemax: Q4 2025 TCE actuals at 34,886 USD/day, outperforming 5TC BCI by 7,455 USD/day net of commissions. Q1 2026 TCE quarter to date rates at 30,673 USD/day (80% fixed).Capesize: Q4 2025 TCE actuals at 30,137 USD/day, outperforming 5TC BCI by 2,706 USD/day net of commissions. Q1 2026 TCE quarter to date rates at 26,725 USD/day (72% fixed).Kamsarmax/Panamax: Q4 2025 TCE actuals at 17,337 USD/day, outperforming 5TC BPI-82 by 2,109 USD/day net of commissions. Q1 2026 TCE quarter to date rates at 13,207 USD/day (66% fixed).
Euronav – Tanker Markets2
Both OPEC and non-OPEC supply ended 2025 at elevated levels. Over the full year, non-OPEC crude oil and condensate supply averaged 1.2 mb/d higher than in 2024. In addition, since March 2025, OPEC’s production quota increased by 2.9 mb/d, while actual output rose by 0.5 mb/d over the same period.
The crude oil tanker market strengthened markedly in late 2025, with the VLCC and Suezmax segments recording their highest earnings in several years. Key drivers were crude oil supply growth and increased volumes of oil-on-water. During 2025, global inventories of crude oil and refined products rose by 529 million barrels, reflecting oil that has been produced but not yet consumed, including in-transit volumes. China continued stockpiling in line with its mandate, hitting a record high crude import of 13.2 mb/d in December 2025. China's crude inventories built at near-record levels in December, rising by 31.3 million barrels. Newly implemented sanctions also reduced the effectiveness of the non-compliant tanker fleet.
The resulting tightening in effective fleet capacity pushed freight rates significantly higher. VLCC spot earnings in Q4 2025 averaged about 102,414 USD/day, more than double the 10-year Q4 average of 47,986 USD/day. Suezmax spot earnings in Q4 2025 averaged 77,370 USD/day, almost double the 10-year Q4 average of 43,507 USD/day. By mid-Q4, VLCC spot rates consistently exceeded 100,000 USD/day, reflecting a limited supply of available tonnage.
OPEC and non-OPEC supply growth also sets up the market for a surplus in the 2026 crude oil-only balance. Agencies differ in their views on the size of this surplus: the IEA estimates a +4.00 mb/d balance, the EIA +2.30 mb/d, while OPEC projects equilibrium. As a result, seaborne crude oil demand is currently driven less by end-consumer consumption and more by inventory accumulation in China and by OPEC+ maintaining market share over price. If these trends continue at similar rates, global inventories could approach the Covid-era peak of May 2020 by the end of 2026, supporting seaborne crude transportation through the remainder of 2026. A continued surplus would pressure oil prices and encourage further inventory building, which has historically supported tanker rates in the short term. Over time, however, sustained lower prices would increase the likelihood of OPEC+ production cuts, which would reduce tanker demand.
Higher charter rates have been accompanied by higher asset values. Second-hand VLCC and Suezmax prices are at their highest levels in 20 years. Clarksons data shows that ten-year-old VLCC values increased from approximately USD 43 million in 2020 to over USD 90 million by the end of 2025 (Suezmax 10-year-old: USD 28 million in 2020 to over USD 64 million by the end of 2025).
Geopolitics continue to influence crude trade patterns. Russia’s war in Ukraine and related sanctions have redirected exports from Europe toward Asia and led to complex compliance and non-compliance practices that reshape tanker flows and lengthen shipping routes. Instability in Iran and around the Strait of Hormuz presents ongoing risk to a key global chokepoint. Red Sea disruptions have reduced traffic through important maritime routes, forcing detours and increasing transport costs. Political pressure on Venezuelan exports and shadow fleet activity continue to alter Atlantic Basin trade, while China’s role as a major buyer of sanctioned barrels means that changes in sanction policy or enforcement could quickly affect tanker demand and deployment. These dynamics remain fluid and complex, making short-term impacts on the compliant tanker fleet difficult to predict.
Market fundamentals indicate continued medium-term strength into H1 2026. Fleet supply growth is accelerating with a Suezmax OB/F of 22.1%, and VLCC OB/F of 18.8%. However, approximately 18–19% of the existing fleet are aged 20 years or older (40%>15 years), implying elevated scrapping potential (once market rates cool down and non-compliant crude tankers become idle).
Euronav has 3 (+3NB) VLCCs (average age 4.9y) and 17 (+2NB) Suezmaxes (average age 6.9y) on the water. Q3 2025 Performance Highlights:
VLCC: actual Q4 TCE for VLCC of 74,842 USD/day and actual Q1 2026 quarter-to-date of 74,465 USD/day (78% fixed)Suezmax: actual Q4 TCE for Suezmax of 64,543 USD/day and actual Q1 2026 quarter-to-date of 61,809 USD/day (87% fixed) Delphis – Container Markets3
Container freight markets remain supported but cyclical risks are further building. Spot rates are moderate overall, underpinned by firm pre–Lunar New Year demand. The SCFI stood just below 1,500 in mid-January—around 40% below the elevated 2024 average but still ~50% above 2023 levels.
Supply growth is set to outpace demand over the medium term. Containership fleet capacity is projected to expand with 4.5% in 2026, accelerating to 6.4% by 2027, materially above expected volume growth and likely to drive rate normalisation. Container trade growth is forecasted to slow to 2.5% this year amid tariff headwinds—particularly on the Transpacific—and with Asia–Europe and secondary trades moderating from the exceptionally strong levels seen in 2025. A steadier 3.0% growth profile is forecasted for 2027.
Red Sea disruption remains the key swing factor. Rerouting is currently adding 11.0% to global TEU-mile demand and is the main uphold to earnings and utilisation. Any de-escalation would remove this support and accelerate the move toward materially weaker market conditions. While carriers may respond through capacity management and higher demolition, the risk is skewed to a more challenging rate environment ahead, with another wave of supply (>4m TEU on order for 2028) building in the background.
CMB.TECH’s 4 x 6,000 TEU (average age 1.8y) and 1 NB 1,400 TEU container vessels are all employed under 10 to 15-year time charter contracts.
Bochem – Chemical Markets4
The chemical tanker markets have shown signs of gradual easing through-out 2025, albeit from a robust starting point earlier in 2024. Demand remains closely tied to global GDP growth. Seaborne trade volumes appear to have been negative in 2025 (-0.8% billion tonne-miles), as tariff volatility weighed on arbitrage activity.
The global chemical tanker orderbook now stands at 18.8% of the existing fleet. The current fleet has an average age of 18 years, with 26% of vessels aged 20 years or older, suggesting that much of the orderbook should primarily serve as replacement tonnage. Nevertheless, the risk of oversupply could emerge in 2026 to 2027, depending on demand growth. 2025 net fleet growth was 3.7%, accelerating to 9.7% in 2026 and 5.9% in 2027, before easing to below 3% in 2028, assuming no additional ships are ordered.
Low ton-mile growth for 2026 and 2027 of 0.8% and 0.9%, respectively, and swing product tankers continue to be a factor in effective supply, although their impact is currently limited. While a strong product tanker market could reduce effective fleet growth somewhat, we do not expect this to be sufficient to halt the anticipated downtrend in earnings.
Bochem 25,000 DWT chemical tankers fleet comprises out of 8 delivered vessels, and 8 NB vessels (average age <1y). They are employed under a 10-year time charter (6 vessels), under a 7-year time charter (6 vessels), and in a spot pool (2 vessels). Q4 2025 performance highlights:
Bochem achieved TCE Q4 2025 of USD 20,887 per day USD/day (spot pool) Q1 2026 spot rates to-date: USD 17,878 per day (spot pool) Windcat – Offshore Energy Markets5
Nine North Sea countries have signed a binding offshore wind investment pact, with the UK, Germany and the Netherlands—Europe’s three core offshore wind markets—all participating. Under the agreement, governments commit to accelerating offshore wind deployment through large-scale, cross-border projects and coordinated infrastructure planning. The countries had previously pledged to develop 300GW of offshore wind by 2050; the new pact reportedly earmarks 100GW of this capacity for joint development. For context, Europe currently has only 36GW of installed offshore wind, implying a step-change in the medium- to long-term build-out trajectory. Reports suggest up to 20GW of jointly developed capacity could already be underway by 2030. The joint declaration said the governments would also step up their efforts to increase financing for wind projects, potentially including through guarantees from the EU budget, and subsidy frameworks like CfD (contracts for difference).
From a vessel market perspective, this confirmation is important. It gives confidence in the medium-term pipeline and validates the scale of construction and O&M demand, following a period where negative headlines through 2025 had raised concerns around project progression.
CSOV demand strengthened through Q4 2025, allowing a large portion of the fleet to secure employment through the winter (off)season. In addition to near-term activity, a material increase is noticeable in contract opportunities for the 2026 season and beyond, with a significant share of projects still unfixed. While some vessel availability is expected in Q1 2026, utilisation should rise sharply from April, with the majority of the European CSOV fleet effectively committed. Incremental availability is not expected to return before late Q3 2026.
Rates and earnings momentum is building in the CSOV market. Owners with open capacity in 2026 are well positioned to benefit from a tightening market, a trend already reflected in rate indications for next year’s work. The supply–demand balance is further supported by rising oil & gas-related demand (including outside Europe) and a sharp slowdown in speculative newbuild ordering over the past 12 months.
Medium-term setup remains constructive. The reduction in new orders should moderate fleet growth from 2028 onwards, while underlying CSOV demand from offshore wind and oil & gas is expected to continue expanding.
In general, we see orders for offshore wind vessels reducing, including CSOVs: 2024 #19 NB orders, and 2025 #9 NB orders – with 16 C/SOVs delivered throughout 2025, while 15 CSOVs are scheduled to be delivered throughout 2026. CSOV fleet stands today at 71 vessels versus an orderbook of 50 vessels (OB/F 70.4%).
CTV fleet utilisation remained high at the start of Q4 2025, although a number of vessels, particularly smaller and 12-pax units, were redelivered to owners in October and November as seasonal activity tapered. Spot chartering during the quarter was limited to minor crew-change and cargo-transfer work. That said, a meaningful volume of 2026 season requirements entered the market, several of which have already been fixed, with additional fixtures expected early in Q1, improving forward revenue visibility.
CTV fleet stands at 731 units with 101 units on order (OB/F 13.8%). As newbuilding levels are relatively modest, it is not expected that supply will exceed demand and hence market conditions are likely to remain familiar (including the typical seasonal patterns).
Windcat has 2 (+5NB) CSOVs, and 59(+4NB) CTVs (average age 9.43y). Q4 2025 performance highlights:
CSOVs: achieved TCE Q4 2025 of USD 108,046 per day. CSOV Q1 2026 spot rates to-date: so far 50.0% fixed at USD 69,900 per dayCTVs: achieved TCE Q4 2025 of USD 2,883 per day. CTV Q1 2026 spot rates to-date: so far 68.8% fixed at USD 2,472 per day CONFERENCE CALL
The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the “Investor Relations” page of the website. The presentation, recording & transcript will also be available on this page.
Webcast Information Event Type: Audio webcast with user-controlled slide presentationEvent Date:26 February 2026Event Time:8 a.m. EST / 2 p.m. CETEvent Title: “Q4 2025 Earnings Conference Call”Event Site/URL: https://events.teams.microsoft.com/event/5ed65c96-e28b-44be-a75a-6ca20467b7eb@d0b2b045-83aa-4027-8cf2-ea360b91d5e4 To attend this conference call, please register via the following link.
Telephone participants who are unable to pre-register may dial in to the respective number of their location (to be found here). The Phone conference ID is the following: 273 707 348#
Publication final year results – 31 March 2026
About CMB.TECH
CMB.TECH (all capitals) is one of the largest listed, diversified and future-proof maritime groups in the world with a combined fleet of about 250 vessels: dry bulk vessels, crude oil tankers, chemical tankers, container vessels, offshore energy vessels and port vessels. CMB.TECH also offers hydrogen and ammonia fuel to customers, through own production or third-party producers.
CMB.TECH is headquartered in Antwerp, Belgium, and has offices across Europe, Asia, United States and Africa.
CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol “CMBT” and on Euronext Oslo Børs under the ticker symbol “CMBTO”.
More information can be found at https://cmb.tech
Forward-Looking Statements
Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbour protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbour legislation. The words "believe", "anticipate", "intends", "estimate", "forecast", "project", "plan", "potential", "may", "should", "expect", "pending" and similar expressions identify forward-looking statements.
The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.
In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the failure of counterparties to fully perform their contracts with us, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for tanker vessel capacity, changes in our operating expenses, including bunker prices, dry-docking and insurance costs, the market for our vessels, availability of financing and refinancing, charter counterparty performance, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hires and other factors. Please see our filings with the United States Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.
This information is published in accordance with the requirements of the Continuing Obligations on Euronext Oslo Børs.
Condensed consolidated interim statement of financial position (unaudited)
(in thousands of USD)
December 31, 2025 December 31, 2024ASSETS Non-current assets Vessels 6,323,773 2,617,484Assets under construction 738,298 628,405Right-of-use assets 4,847 1,910Other tangible assets 23,981 21,628Prepayments 1,075 1,657Intangible assets 12,710 16,187Goodwill 177,022 —Receivables 98,618 75,076Investments 111,346 61,806Deferred tax assets 2,850 10,074 Total non-current assets 7,494,520 3,434,227 Current assets Inventory 77,175 26,500Trade and other receivables 319,341 235,883Current tax assets 4,912 3,984Cash and cash equivalents 146,529 38,869 547,957 305,236 Non-current assets held for sale 363,097 165,583 Total current assets 911,054 470,819 TOTAL ASSETS 8,405,574 3,905,046 EQUITY and LIABILITIES Equity Share capital 343,440 239,148Share premium 1,817,557 460,486Translation reserve 9,502 (2,045)Hedging reserve 90 2,145Treasury shares (284,508) (284,508)Retained earnings 738,241 777,098 Equity attributable to owners of the Company 2,624,322 1,192,324 Non-current liabilities Bank loans 2,839,590 1,450,869Other notes — 198,887Other borrowings 1,876,795 667,361Lease liabilities 3,368 1,451Other payables 20 —Employee benefits 1,180 1,060Deferred tax liabilities 485 438 Total non-current liabilities 4,721,438 2,320,066 Current liabilities Trade and other payables 208,857 79,591Current tax liabilities 8,288 9,104Bank loans 351,170 201,937Other notes 203,287 3,733Other borrowings 286,531 95,724Lease liabilities 1,681 2,293Provisions — 274 Total current liabilities 1,059,814 392,656 TOTAL EQUITY and LIABILITIES 8,405,574 3,905,046 Condensed consolidated interim statement of profit or loss (unaudited)
(in thousands of USD except per share amounts)
2025 2024 Jan. 1 - Dec. 31, 2025 Jan. 1 - Dec. 31, 2024Shipping income Revenue 1,666,223 940,246Gains on disposal of vessels/other tangible assets 192,568 635,019Other operating income 29,613 50,660Total shipping income 1,888,404 1,625,925 Operating expenses Raw materials and consumables (10,265) (3,735)Voyage expenses and commissions (362,155) (174,310)Vessel operating expenses (420,409) (199,646)Charter hire expenses (3,124) (138)Loss on disposal of vessels/other tangible assets (4) (2)Depreciation tangible assets (384,684) (163,148)Amortisation intangible assets (3,284) (2,881)Impairment losses (5,354) (1,847)General and administrative expenses (143,284) (77,766)Total operating expenses (1,332,563) (623,473) RESULT FROM OPERATING ACTIVITIES 555,841 1,002,452 Finance income 28,729 38,689Finance expenses (433,359) (169,339)Net finance expenses (404,630) (130,650) Share of profit (loss) of equity accounted investees (net of income tax) (882) 920 PROFIT (LOSS) BEFORE INCOME TAX 150,329 872,722 Income tax benefit (expense) (10,185) (1,893) PROFIT (LOSS) FOR THE PERIOD 140,144 870,829 Attributable to: Owners of the company 161,698 870,829Non-controlling interest (21,554) — Basic earnings per share 0.70 4.44Diluted earnings per share 0.70 4.44 Weighted average number of shares (basic) 229,443,392 196,041,579Weighted average number of shares (diluted) 229,443,392 196,041,579 Condensed consolidated interim statement of comprehensive income (unaudited)
(in thousands of USD)
2025 2024 Jan. 1 - Dec. 31, 2025 Jan. 1 - Dec. 31, 2024 Profit/(loss) for the period 140,144 870,829 Other comprehensive income (expense), net of tax Items that will never be reclassified to profit or loss: Remeasurements of the defined benefit liability (asset) 88 200 Items that are or may be reclassified to profit or loss: Foreign currency translation differences 11,547 (2,280)Cash flow hedges - effective portion of changes in fair value (2,055) 1,005 Other comprehensive income (expense), net of tax 9,580 (1,075) Total comprehensive income (expense) for the period 149,724 869,754 Attributable to: Owners of the company 171,278 869,754Non-controlling interest (21,554) — Condensed consolidated interim statement of changes in equity (unaudited)
Share capitalShare premiumTranslation reserveHedging reserveTreasury sharesRetained earningsEquity attributable to owners of the CompanyNon-controlling interestTotal equity Balance at January 1, 2024239,1481,466,5292351,140(157,595)807,9162,357,373—2,357,373 Total comprehensive income (expense) — —(2,280)1,005 —871,029869,754—869,754 Total transactions with owners — (1,006,043) — — (126,913) (901,847)(2,034,803)—(2,034,803) Balance at December 31, 2024239,148460,486(2,045)2,145(284,508)777,0981,192,324—1,192,324 Share capitalShare premiumTranslation reserveHedging reserveTreasury sharesRetained earningsEquity attributable to owners of the CompanyNon-controlling interestTotal equity Balance at January 1, 2025239,148460,486(2,045)2,145(284,508)777,0981,192,324—1,192,324 Total comprehensive income (expense) — —11,547(2,055) —161,786171,278(21,554)149,724 Total transactions with owners104,2921,357,071———(200,643)1,260,72021,5541,282,274 Balance at December 31, 2025343,4401,817,5579,50290(284,508)738,2412,624,322—2,624,322 (In thousands of USD)
Condensed consolidated interim statement of cash flows (unaudited)
(in thousands of USD)
2025 2024 Jan. 1 - Dec. 31, 2025 Jan. 1 - Dec. 31, 2024 Net cash from (used in) operating activities 438,313 459,064 Net cash from (used in) investing activities (1,621,677) (680,230) Net cash from (used in) financing activities 1,291,667 (172,971) Net increase (decrease) in cash and cash equivalents 108,304 (394,137) Net cash and cash equivalents at the beginning of the period 38,869 429,370Effect of changes in exchange rates (644) 3,636 Net cash and cash equivalents at the end of the period 146,529 38,869 1 Source: AXS Marine, Clarksons SIN, Breakwave Advisors, Morgan Stanley, BRS, Intermodal, Deutsche Bank, Allied, S&P Global
2 Source: AXS Marine, Clarksons SIN, IEA, Morgan Stanley, Goldman Sachs
3 Source: Clarksons SIN
4 Source: Clarksons SIN, Stolt Pool
5 Source: Clarksons Offshore, Reuters, Spinergie
Q4_2025_Earnings_release_ENG (1)
2026-02-26 05:1617d ago
2026-02-25 23:1317d ago
Nvidia's Record Revenue, Data Center Demand Serves As Backdrop For Rally In AI-Based Crypto Tokens
Artificial intelligence-related cryptocurrencies were rallying late Wednesday amid AI darling Nvidia Corp.'s (NASDAQ:NVDA) record quarterly revenue and data center demand.
2026-02-26 05:1617d ago
2026-02-25 23:1717d ago
HSBC kicks off Singapore insurance business sale, eyes over $1 billion value, sources say
Item 1 of 2 A Hongkong and Shanghai Banking Corporation (HSBC) logo is displayed outside a bank branch in Sydney, Australia, August 19, 2025. REUTERS/Hollie Adams
[1/2]A Hongkong and Shanghai Banking Corporation (HSBC) logo is displayed outside a bank branch in Sydney, Australia, August 19, 2025. REUTERS/Hollie Adams Purchase Licensing Rights, opens new tab
HONG KONG, Feb 26 (Reuters) - HSBC (HSBA.L), opens new tab has started the sale process for its Singapore life insurance product manufacturing business with the hiring of an adviser, and is hoping for the deal to be valued at more than $1 billion, said three sources with knowledge of the matter.
The bank, which makes the bulk of its revenues and profits in Asia, has hired JPMorgan (JPM.N), opens new tab as its adviser, said two of the sources, who declined to be named as they were not authorised to speak to the media.
The Reuters Inside Track newsletter is your essential guide to the biggest events in global sport. Sign up here.
HSBC has started engaging with potential buyers including Japanese insurers Nippon Life and Dai-ichi Life (8750.T), opens new tab, and non-binding bids for the business could be expected in a month, said one of the sources.
HSBC, JPMorgan, and Dai-ichi Life declined to comment on the potential sale of the Singapore insurance manufacturing business. Nippon Life did not immediately respond to a Reuters request for comment.
Reporting by Kane Wu and Selena Li in Hong Kong, additional reporting by Jemima Denham of The Insurer in London and Anton Bridge in Tokyo; Editing by Sumeet Chatterjee and Muralikumar Anantharaman
Our Standards: The Thomson Reuters Trust Principles., opens new tab
2026-02-26 05:1617d ago
2026-02-25 23:1717d ago
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust remains a hold as dividend coverage and NAV erosion persist amid elevated rates. GBAB offers a 9.8% yield and monthly payouts but relies on net realized gains to cover distributions, risking long-term NAV decline. 84.84% of GBAB's portfolio is investment grade, limiting default risk, yet leverage (30.29% of assets) amplifies downside in adverse markets.
2026-02-26 05:1617d ago
2026-02-25 23:2517d ago
"No way" India will go back to the same deal under new tariffs: Ex-WTO Envoy
Jayant Dasgupta, former Indian Ambassador to the World Trade Organization, says India is within its rights to withdraw the tariff concessions it had extended to the US, as one side has altered tariff rates, effectively reopening the agreement for negotiation. He adds that, in his view, India is likely to be in a relatively advantageous position compared with its Asian peers under the new 15% tariff regime.
2026-02-26 05:1617d ago
2026-02-25 23:2717d ago
Veeco Instruments Inc. (VECO) Q4 2025 Earnings Call Transcript
, /PRNewswire/ -- Dingdong (Cayman) Limited (the "Company") (NYSE: DDL), a leading fresh grocery e-commerce company in China, announces that the record date for the purpose of determining the eligibility of the holders of the Class A ordinary shares and the Class B ordinary shares of the Company, par value US$ 0.000002 each (the "Ordinary Shares"), to vote and attend the forthcoming 2026 annual general meeting of the Company (the "AGM"), will be as of the close of business on Monday, March 9, 2026, Shanghai time (the "Ordinary Share Record Date").
In order to be eligible to vote and attend the AGM, with respect to Ordinary Shares registered on the Company's principal share register in the Cayman Islands, all valid documents for the transfers of shares accompanied by the relevant share certificates must be lodged with the Company's principal share registrar and transfer office, Maples Fund Services (Cayman) Limited, PO Box 1093, Boundary Hall, Cricket Square, Grand Cayman, KY1-1102, Cayman Islands, no later than 6:00 p.m. on Friday, March 6, 2026, Cayman Islands time (due to the time difference between the Cayman Islands and Shanghai). All persons who are registered holders of the Ordinary Shares on the Ordinary Share Record Date will be entitled to vote and attend the AGM.
Holders of American depositary shares (the "ADSs") issued by Deutsche Bank Trust Company Americas as the depositary of the ADSs (the "Depositary"), each two representing three Class A ordinary shares of the Company, may attend, but may not vote at, the AGM. The ADS holders as of the close of business on Friday, March 6, 2026, New York time (the "ADS Record Date", together with the Ordinary Share Record Date, the "Record Date"), after receiving the voting materials from the Depositary, will be able to instruct the Depositary, being the holder of record of the Class A ordinary shares represented by the ADSs, as to how to vote the Class A ordinary shares represented by such ADSs. The Depositary will endeavor, to the extent practicable and legally permissible, to vote or cause to be voted at the AGM the Class A ordinary shares represented by the ADSs in accordance with the instructions that it has properly and timely received from the ADS holders. Please be aware that, because of the time difference between Shanghai and New York, any ADS holders that cancel their ADSs in exchange for Class A ordinary shares on Friday, March 6, 2026, New York time will no longer be ADS holders with respect to such canceled ADSs as of the ADS Record Date and will not be able to instruct the Depositary as to how to vote the Class A ordinary shares represented by such canceled ADSs as described above; such ADS holders will also not be holders of the Class A ordinary shares represented by such canceled ADSs as of the Ordinary Share Record Date for the purpose of determining the eligibility to attend and vote at the AGM.
About Dingdong (Cayman) Limited
Dingdong (Cayman) Limited is a leading fresh grocery e-commerce company in mainland China, with sustainable long-term growth. We directly provide users and households with fresh groceries, prepared food, and other food products through delivering a convenient and excellent shopping experience supported by an extensive self-operated frontline fulfillment grid. Leveraging our deep insights into consumers' evolving needs and our strong food innovation capabilities, we have successfully launched a series of private label products spanning a variety of food categories. Many of our private label products are produced at our Dingdong production plants, allowing us to more efficiently produce and offer safe and high-quality food products. We aim to be the first choice for fresh and food shopping.
For more information, please visit: https://ir.100.me.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "confident," "potential," "continue," or other similar expressions. Among other things, business outlook and quotations from management in this announcement, as well as Dingdong's strategic, operational, share repurchase and dividend plans, contain forward-looking statements. Dingdong may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its interim and annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Dingdong's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the successful completion of the Transaction; Dingdong's goals and strategies; Dingdong's future business development, financial conditions, and results of operations; the expected outlook of the on-demand e-commerce market in China; Dingdong's expectations regarding demand for and market acceptance of its products and services; Dingdong's expectations regarding its relationships with its users, clients, business partners, and other stakeholders; competition in Dingdong's industry; Dingdong's proposed use of proceeds; and relevant government policies and regulations relating to Dingdong's industry, and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this announcement and in the attachments is as of the date of the announcement, and the Company undertakes no duty to update such information, except as required under applicable law.